[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 310
36. Tsao KC, Wu TL, Chang PY, Hong JH, Wu JT: Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers. J Clin Lab Anal; 2006;20(2):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 73,443 asymptomatic individuals were screened on a voluntary basis for cancer at Chang Gung Memorial Hospital in Taiwan using a panel of tumor markers, including alpha fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, carcinoembryonic antigen (CEA), prostate specific antigen (PSA), chromogranin A (CgA), and squamous cell specific antigen (SCC).
  • Of the tumor markers monitored, elevated CA 19-9, CEA, and CA 125 were the most frequently detected in a variety of cancers.
  • Screening with multiple circulating tumor markers provides improved sensitivity for cancer detection in asymptomatic individuals before they reach the fatal advanced stage.
  • [MeSH-major] Asian Continental Ancestry Group. Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Mass Screening / methods
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. CA-19-9 Antigen / analysis. Cohort Studies. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Sex Distribution. Taiwan / epidemiology


37. Koutros S, Mahajan R, Zheng T, Hoppin JA, Ma X, Lynch CF, Blair A, Alavanja MC: Dichlorvos exposure and human cancer risk: results from the Agricultural Health Study. Cancer Causes Control; 2008 Feb;19(1):59-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dichlorvos exposure and human cancer risk: results from the Agricultural Health Study.
  • OBJECTIVES: We evaluated cancer risk from DDVP (2,2-Dichloroethenyl dimethylphosphate) exposure among pesticide applicators enrolled in the Agricultural Health Study (AHS) cohort.
  • METHODS: The AHS is a cohort of 57,311 pesticide applicators in North Carolina and Iowa, enrolled from 1993 to 1997 and followed for cancer through 2004.
  • Poisson regression analysis was used to calculate rate ratios (RR) and 95% confidence intervals (CI) to evaluate the association of DDVP exposure among 2,943 incident cases of cancer.
  • RESULTS: DDVP exposure was not associated with any cancer studied here.
  • We observed no elevation in risk among lymphohematopoietic cancers, RR = 1.00 (95% CI 0.51, 1.96) and a small excess risk associated with exposure among those with a family history of prostate cancer (RR = 1.18 (95% CI 0.73, 1.82).
  • CONCLUSION: We find little evidence of an association between cumulative lifetime use of DDVP and risk of any cancer at this stage of follow up of the AHS.

  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DICHLORVOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epidemiology. 2002 Jan;13(1):94-9 [11805592.001]
  • [Cites] Environ Health Perspect. 2006 Dec;114(12):1838-42 [17185272.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Sep;12(5):313-8 [12198579.001]
  • [Cites] Bull Exp Biol Med. 2002 Jun;133(6):594-6 [12447476.001]
  • [Cites] J Occup Environ Med. 2003 Mar;45(3):249-58 [12661182.001]
  • [Cites] Am J Epidemiol. 2003 May 1;157(9):800-14 [12727674.001]
  • [Cites] Occup Environ Med. 2003 Sep;60(9):E11 [12937207.001]
  • [Cites] Environ Health Perspect. 2004 Apr;112(5):631-5 [15064173.001]
  • [Cites] Toxicology. 2004 Nov 1;204(1):41-50 [15369847.001]
  • [Cites] Lancet. 1981 Aug 8;2(8241):300-1 [6114336.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6585-91 [2208120.001]
  • [Cites] Ecotoxicol Environ Saf. 1991 Aug;22(1):79-87 [1914997.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2447-55 [1568215.001]
  • [Cites] Arch Environ Contam Toxicol. 1992 Apr;22(3):260-6 [1616309.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1991;53:5-586 [1688189.001]
  • [Cites] Toxicology. 1996 Apr 15;108(1-2):49-56 [8644117.001]
  • [Cites] Environ Health Perspect. 1996 Apr;104(4):362-9 [8732939.001]
  • [Cites] Adv Ther. 2005 Mar-Apr;22(2):107-16 [16020401.001]
  • [Cites] Regul Toxicol Pharmacol. 2006 Apr;44(3):238-48 [16439043.001]
  • [Cites] Ann Occup Hyg. 2002 Mar;46(2):245-60 [12074034.001]
  • (PMID = 17943454.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / TU2 CA105666; United States / Intramural NIH HHS / / Z01 ES049030-11; United States / NCI NIH HHS / CA / TU2 CA 105666
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Insecticides; 7U370BPS14 / Dichlorvos
  • [Other-IDs] NLM/ NIHMS44535; NLM/ PMC2822646
  •  go-up   go-down


38. Wolff MS, Teitelbaum SL, Pinney SM, Windham G, Liao L, Biro F, Kushi LH, Erdmann C, Hiatt RA, Rybak ME, Calafat AM, Breast Cancer and Environment Research Centers: Investigation of relationships between urinary biomarkers of phytoestrogens, phthalates, and phenols and pubertal stages in girls. Environ Health Perspect; 2010 Jul;118(7):1039-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We measured urinary exposure biomarkers at visit 1 and examined associations with breast and pubic hair development (present or absent, assessed 1 year later) using multivariate adjusted prevalence ratios (PR) and 95% confidence intervals (CIs).
  • High-molecular-weight phthalate (high MWP) metabolites were weakly associated with pubic hair development [adjusted PR, 0.94 (95% CI, 0.88-1.00), fifth vs. first quintile].
  • Small inverse associations were seen for daidzein with breast stage and for triclosan and high MWP with pubic hair stage; a positive trend was observed for low-molecular-weight phthalate biomarkers with breast and pubic hair development.
  • In the first enterolactone quintile, for the association of high BMI with any development, the PR was 1.34 (95% CI, 1.23-1.45 vs. low BMI).

  • MedlinePlus Health Information. consumer health - Puberty.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. PHTHALIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Data. 2000 Jun 8;(314):1-27 [11183293.001]
  • [Cites] Pediatrics. 2010 Sep;126(3):e583-90 [20696727.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):113-8 [12650707.001]
  • [Cites] N Engl J Med. 2003 Apr 17;348(16):1527-36 [12700372.001]
  • [Cites] Environ Health Perspect. 2003 May;111(5):737-41 [12727603.001]
  • [Cites] Am J Epidemiol. 2004 Apr 1;159(7):702-6 [15033648.001]
  • [Cites] Clin Chem. 2004 May;50(5):924-32 [15105350.001]
  • [Cites] Environ Health Perspect. 2004 May;112(6):751-3 [15121520.001]
  • [Cites] Tijdschr Kindergeneeskd. 1985 Aug;53(4):147-52 [4082170.001]
  • [Cites] Am J Epidemiol. 1993 Jan 1;137(1):1-8 [8434568.001]
  • [Cites] Cancer Causes Control. 1995 Nov;6(6):567-73 [8580306.001]
  • [Cites] Epidemiology. 1999 Jan;10(1):37-48 [9888278.001]
  • [Cites] Anal Chem. 2005 May 1;77(9):2985-91 [15859620.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5407-13 [16097788.001]
  • [Cites] J Pharm Biomed Anal. 2006 Mar 3;40(4):928-42 [16182503.001]
  • [Cites] Mol Cell Endocrinol. 2006 Jul 25;254-255:187-201 [16720078.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 21;844(1):53-9 [16893688.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):116-21 [17366830.001]
  • [Cites] Environ Health Perspect. 2007 Oct;115(10):1467-73 [17938737.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jan 1;861(1):145-50 [18068558.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2008 Feb;102(2):168-75 [18226071.001]
  • [Cites] Environ Res. 2008 Feb;106(2):257-69 [17976571.001]
  • [Cites] Pediatrics. 2008 Feb;121 Suppl 3:S208-17 [18245513.001]
  • [Cites] Environ Health Perspect. 2008 Apr;116(4):467-73 [18414628.001]
  • [Cites] Environ Res. 2008 Jul;107(3):393-400 [18479682.001]
  • [Cites] Curr Opin Endocrinol Diabetes Obes. 2009 Feb;16(1):25-30 [19115521.001]
  • [Cites] J Pediatr Endocrinol Metab. 2009 Jan;22(1):69-77 [19344077.001]
  • [Cites] Toxicol Lett. 2009 Dec 1;191(1):9-14 [19643168.001]
  • [Cites] Environ Health Perspect. 2000 Aug;108(8):723-9 [10964792.001]
  • (PMID = 20308033.001).
  • [ISSN] 1552-9924
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / ES/CA012770; United States / NIEHS NIH HHS / ES / U01 ES012800; United States / NIEHS NIH HHS / ES / P01 ES009584; United States / NIEHS NIH HHS / ES / ES012800; United States / NCRR NIH HHS / RR / UL1 RR024131; United States / NIEHS NIH HHS / ES / ES012645; United States / NCRR NIH HHS / RR / M01 RR000071; United States / NIEHS NIH HHS / ES / K01 ES012645; United States / NIEHS NIH HHS / ES / ES012801; United States / NIEHS NIH HHS / ES / U01 ES012771; United States / NIEHS NIH HHS / ES / ES012771; United States / NCI NIH HHS / CA / CA93447; United States / NCRR NIH HHS / RR / UL1-RR024131; United States / NIEHS NIH HHS / ES / U01 ES012801; United States / NIEHS NIH HHS / ES / ES009584; United States / NIEHS NIH HHS / ES / U01 ES019454; United States / NCI NIH HHS / CA / K07 CA093447; United States / NCRR NIH HHS / RR / MO1-RR-00071
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phenols; 0 / Phthalic Acids; 0 / Phytoestrogens; 6O7F7IX66E / phthalic acid
  • [Other-IDs] NLM/ PMC2920905
  • [Investigator] Collman G; Winn D; Maull E; Reinlib L; Lynch S; Ellison G; Dilworth C; Galvez M; Brenner B; Wetmur J; Chen J; Sheffield P; Vangeepurum N; Forman J; Boguski L; Britton J; Peter S; Mejia A; Richiez A; Montana J; Chae E; Osborne R; Moshier E; Zhu C; McGovern K; Dahl C; Baker C; Myatt S; Ford K; Bornschein B; Yaghjyan L; Roda S; Greenspan L; Sternfeld B; Ambrosone C; Deardorff J; Stewart S; Balke K; Ashley C; Bonnell C; Beeck A; Chan C; Davis D; Landaverde E; Burleson S; Lum R; Mirabedi A; Trotter M; Silva M; Samandar E; Preau J; Ye X; Bishop A; Reidy J; Pfeiffer C; Parker D; Olive P; Kimberly M; Dodson C; Claudio L; Williams S; Duncan D; Fonfa A; Barlow J; Koblick K; Brown K; Ball K
  •  go-up   go-down


39. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG: The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer; 2008 Jul 22;99(2):341-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.
  • Ovarian cancer is the most frequent cause of death from gynaecological cancer in the Western world.
  • Current prognostic factors do not allow reliable prediction of response to chemotherapy and survival for individual ovarian cancer patients.
  • Epidermal growth factor receptor (EGFR) and HER-2/neu are frequently expressed in ovarian cancer but their prognostic value remains unclear.
  • In this study, we investigated the expression and prognostic value of EGFR, EGFR variant III (EGFRvIII), HER-2/neu and important downstream signalling components in a large series of epithelial ovarian cancer patients.
  • Our results show that negative PTEN immunostaining was associated with stage I/II disease (P=0.006), non-serous tumour type (P=0.042) and in multivariate analysis with a longer progression-free survival (P=0.015).
  • Negative PTEN staining also predicted improved progression-free survival in patients with grade III or undifferentiated serous carcinomas (P=0.011).
  • Positive pAKT staining was associated with advanced-stage disease (P=0.006).


40. Gavioli M, Losi L, Luppi G, Iacchetta F, Zironi S, Bertolini F, Falchi AM, Bertoni F, Natalini G: Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):370-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter.
  • PURPOSE: To assess the frequency and magnitude of changes in lower rectal cancer resulting from preoperative therapy and its impact on sphincter-saving surgery.
  • Preoperative therapy can increase the rate of preserving surgery by shrinking the tumor and enhancing its distance from the anal sphincter.
  • METHODS AND MATERIALS: A total of 98 cases of locally advanced cancer of the lower rectum (90 Stage uT3-T4N0-N+ and 8 uT2N+M0) that had undergone preoperative therapy were studied by endorectal ultrasonography.
  • The maximal size of the tumor and its distance from the anal sphincter were measured in millimeters before and after preoperative therapy.
  • The distance between the tumor and the anal sphincter increased in 60.2% of cases.
  • It was possible in nearly 30% of patients in whom the cancer had reached the anal sphincter before the preoperative therapy.
  • CONCLUSION: The results of our study have shown that in very low rectal cancer, preoperative therapy causes tumor downsizing in >80% of cases and in more than one-half enhances the distance between the tumor and anal sphincter.
  • [MeSH-major] Anal Canal / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524570.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


41. Dai Y, Jiang JB, Bi DS, Jin ZT, Sun JZ, Hu SY: Preservation of the continence function after intersphincteric resection using a prolapsing technique in the patients with low rectal cancer and its clinical prognosis. Chin Med J (Engl); 2008 Oct 20;121(20):2016-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preservation of the continence function after intersphincteric resection using a prolapsing technique in the patients with low rectal cancer and its clinical prognosis.
  • BACKGROUND: The technique of intersphincteric resection of tumors combined with coloanal anastomosis has been used to avoid permanent colostomy for patients with a rectal cancer located < 5 cm from the anal verge.
  • This study aimed at assessing the preservation of continence function of the residual rectum and the clinical prognosis of patients with lower rectal cancer after intersphincteric resection using a prolapsing technique.
  • (1) pathological evidence of rectal cancer and the tumors within distal margins located 5 cm or less from the anus by preoperative endoscopic examination;.
  • From January 2000 to June 2004, 23 patients with low rectal cancer were included in this study.
  • The patients were followed for assessment of the function of the residual rectum and of cancer recurrence after the operations.
  • RESULTS: The median tumor distance from the anal margin was 4.5 (range 3.5 - 5.0) cm and the mean distal surgical margin 1.6 (range 1.0 - 2.0) cm.
  • Cancer was classified into Stage I (30.4%), Stage II (47.8%), and Stage III (21.7%) according to the TNM classification.
  • Anal manometer measurements showed a decrease of pressure during the resting time after intersphincteric resection and this change remained during the period of follow-up.
  • CONCLUSIONS: More residual rectum function after the surgery may be preserved by intersphincteric resection of low rectum cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080267.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


42. Jeon SH, Jeon SH, Chang SG: Clinical prognostic factors for radical cystectomy in bladder cancer. Cancer Res Treat; 2005 Feb;37(1):48-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical prognostic factors for radical cystectomy in bladder cancer.
  • PURPOSE: We investigated the effects of radical cystectomy and the prognostic factors that affect the survival of bladder cancer patients.
  • Indications for surgery included muscle invasive bladder cancer and high-risk superficial bladder cancer.
  • The cancer specific and recurrence free survival rates with respect to the possible prognostic factors were determined using Kaplan-Meier statistics.
  • Pathologic stage, tumor grade, mean nuclear area, sex and lymphatic invasion were significant factors by univariate analysis (p<0.05).
  • Multivariate analysis identified pathologic stage and lymphatic invasion as independent prognostic factors.
  • CONCLUSIONS: Radical cystectomy for organ-confined cancer showed favorable 5- and 10-year survival rates.
  • The most significant independent prognostic factors were the pathologic stage and the presence of lymphatic invasion, which were highly correlated with all the investigated disease endpoints.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1979 Jun;43(6):2532-9 [455239.001]
  • [Cites] J Korean Med Sci. 1992 Jun;7(2):154-61 [1524728.001]
  • [Cites] J Urol. 1991 Jan;145(1):45-50 [1984097.001]
  • [Cites] J Urol. 1991 Mar;145(3):459-64; discussion 464-7 [1997689.001]
  • [Cites] J Urol. 1983 Jul;130(1):56-60 [6864915.001]
  • [Cites] Urology. 1980 Aug;16(2):142-4 [7404907.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2142-4 [15150549.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Aug;23(4):251-6 [11531139.001]
  • [Cites] BJU Int. 2002 Mar;89(4):374-8 [11872027.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):460-7 [11872337.001]
  • [Cites] Urology. 2002 Dec;60(6):1124-30 [12475695.001]
  • [Cites] Urol Int. 2004;72(2):103-11 [14963349.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):89-93 [11134199.001]
  • (PMID = 19956510.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2785423
  • [Keywords] NOTNLM ; Bladder cancer / Prognostic factor / Radical cystectomy
  •  go-up   go-down


43. Yatsuoka T, Suto Y, Yokoyama Y, Yamaura T, Nishimura Y, Sakamoto H, Tanaka Y, Nozu S, Nishimura Y, Kurosumi M: [Intramucosal colorectal carcinomas treated by surgical resection]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2563-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stage 0 colorectal cancer was found only in the innermost lining of the colon and rectum.
  • Treatments for an early stage colorectal cancer were available including endoscopic polypectomy, endoscopic mucosal resection (EMR) and trans-anal or -sacral local excision, laparoscopy-assisted colectomy and open colectomy.
  • Our study indicated that endoscopic therapy for the early stage colorectal cancer was more advantageous than the conventional operative treatment.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224640.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


4
Advertisement
4. van der Snoek EM, Amelink A, van der Ende ME, den Hollander JC, den Hollander JG, Kroon FP, Vriesendorp R, Neumann HA, Robinson DJ: Photodynamic therapy with topical metatetrahydroxychlorin (Fosgel) is ineffective for the treatment of anal intraepithelial neoplasia, grade III. J Acquir Immune Defic Syndr; 2009 Sep 1;52(1):141-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with topical metatetrahydroxychlorin (Fosgel) is ineffective for the treatment of anal intraepithelial neoplasia, grade III.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / virology. HIV Infections / complications. Mesoporphyrins / administration & dosage. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19704267.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


45. Scholefield JH, Castle MT, Watson NF: Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg; 2005 Sep;92(9):1133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of high-grade anal intraepithelial neoplasia.
  • BACKGROUND: The natural history of anal intraepithelial neoplasia (AIN) is uncertain.
  • METHODS: All patients were diagnosed with high-grade AIN (AIN III) between 1994 and 2003.
  • Diagnosis was by full-thickness biopsy and histopathological examination.
  • Prospective data were collected regarding recurrence, postoperative complications and progression to invasive carcinoma.
  • Excision of localized high-grade AIN was carried out in 28 patients with minimal morbidity.
  • Six patients were systemically immunosuppressed at diagnosis, all of whom had multifocal perianal lesions.
  • Three immunosuppressed patients developed invasive anal squamous carcinoma during follow-up.
  • CONCLUSION: AIN III appears to have a relatively low potential for malignant transformation in the immunocompetent patient.
  • However, immunosuppressed patients are more likely to have extensive AIN III and a greater risk of malignant change.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Cell Transformation, Neoplastic / pathology
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Prospective Studies

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 British Journal of Surgery Society Ltd.
  • (PMID = 16044425.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Park NY, Valacchi G, Lim Y: Effect of dietary conjugated linoleic acid supplementation on early inflammatory responses during cutaneous wound healing. Mediators Inflamm; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, the wound closure rate was improved significantly in mice fed a 1% CLA-supplemented diet during early stage of wound healing (inflammatory stage).
  • We conclude that dietary CLA supplementation enhances the early stage of cutaneous wound healing as a result of modulating oxidative stress and inflammatory responses.
  • [MeSH-major] Dietary Supplements. Inflammation / pathology. Linoleic Acids, Conjugated. Skin. Wound Healing / drug effects

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2000 Sep;130(9):2285-91 [10958825.001]
  • [Cites] J Trauma. 2009 Jul;67(1):108-12; discussion 112-4 [19590318.001]
  • [Cites] J Agric Food Chem. 2000 Sep;48(9):4162-7 [10995331.001]
  • [Cites] J Agric Food Chem. 2000 Nov;48(11):5469-75 [11087504.001]
  • [Cites] Diabetes. 2001 May;50(5):1149-57 [11334420.001]
  • [Cites] Prog Lipid Res. 2001 Jul;40(4):283-98 [11412893.001]
  • [Cites] J Agric Food Chem. 2001 Jul;49(7):3452-6 [11453790.001]
  • [Cites] Mutat Res. 2001 Sep 1;480-481:243-68 [11506818.001]
  • [Cites] Biochim Biophys Acta. 2002 Apr 15;1581(3):89-99 [12020636.001]
  • [Cites] J Agric Food Chem. 2002 Jul 3;50(14):4135-40 [12083897.001]
  • [Cites] J Neuroimmunol. 2002 Aug;129(1-2):74-83 [12161023.001]
  • [Cites] Toxicology. 2002 Sep 30;179(1-2):163-70 [12204552.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2002 Dec;67(6):435-43 [12468265.001]
  • [Cites] Exp Biol Med (Maywood). 2003 Jan;228(1):51-8 [12524473.001]
  • [Cites] Blood. 2003 Jul 15;102(2):521-8 [12649161.001]
  • [Cites] Physiol Rev. 2003 Jul;83(3):835-70 [12843410.001]
  • [Cites] J Agric Food Chem. 2004 Jan 14;52(1):71-8 [14709015.001]
  • [Cites] J Nutr. 2004 Apr;134(4):811-6 [15051830.001]
  • [Cites] J Clin Invest. 1972 Aug;51(8):2009-23 [5054460.001]
  • [Cites] Am J Pathol. 1975 Jan;78(1):71-100 [1109560.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Cancer Lett. 1979 Jul;7(2-3):63-9 [476611.001]
  • [Cites] Biochem J. 1989 Oct 15;263(2):539-45 [2556998.001]
  • [Cites] Clin Plast Surg. 1990 Jul;17(3):433-42 [2199135.001]
  • [Cites] Arch Surg. 1993 Nov;128(11):1235-41 [8239986.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Feb 15;198(3):1107-12 [8117267.001]
  • [Cites] Atherosclerosis. 1994 Jul;108(1):19-25 [7980704.001]
  • [Cites] Cytokine. 1996 Jul;8(7):548-56 [8891436.001]
  • [Cites] Science. 1997 Apr 4;276(5309):75-81 [9082989.001]
  • [Cites] Trends Pharmacol Sci. 1997 Feb;18(2):46-50 [9090308.001]
  • [Cites] Artery. 1997;22(5):266-77 [9209699.001]
  • [Cites] Lipids. 1997 Aug;32(8):853-8 [9270977.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 27;244(3):678-82 [9535724.001]
  • [Cites] N Engl J Med. 1999 Sep 2;341(10):738-46 [10471461.001]
  • [Cites] Toxicol Lett. 2006 Jan 5;160(2):127-34 [16129572.001]
  • [Cites] J Trauma. 2005 Nov;59(5):1048-51; discussion 1051 [16385276.001]
  • [Cites] J Nutr Biochem. 2006 May;17(5):328-36 [16214328.001]
  • [Cites] Plast Reconstr Surg. 2006 Jun;117(7 Suppl):42S-58S [16799374.001]
  • [Cites] J Am Coll Surg. 2006 Oct;203(4):539-45 [17000399.001]
  • [Cites] J Investig Dermatol Symp Proc. 2006 Sep;11(1):106-11 [17069017.001]
  • [Cites] Carcinogenesis. 2007 Feb;28(2):363-71 [16950795.001]
  • [Cites] Vet J. 2007 Mar;173(2):413-21 [16495095.001]
  • [Cites] Br Poult Sci. 2008 Mar;49(2):213-21 [18409096.001]
  • [Cites] Pharmacol Res. 2008 Aug;58(2):165-71 [18617006.001]
  • [Cites] Annu Rev Biochem. 2000;69:145-82 [10966456.001]
  • (PMID = 20871865.001).
  • [ISSN] 1466-1861
  • [Journal-full-title] Mediators of inflammation
  • [ISO-abbreviation] Mediators Inflamm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Linoleic Acids, Conjugated; 0 / Reactive Oxygen Species; 4Y8F71G49Q / Malondialdehyde; EC 1.14.99.- / Ptgs2 protein, mouse; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.3 / Heme Oxygenase-1; EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ PMC2943105
  •  go-up   go-down


47. Lundqvist H, Antoni G, Långström B: Genotoxic hazard of radiopharmaceuticals in humans: chemical and radiation aspects coupled to microdosing. Eur J Clin Pharmacol; 2007 Jul;63(7):641-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: To obtain the pharmacokinetic properties of drug candidates at an early stage of the development process, a microdosing (phase 0) concept to radiolabel drug candidates and administer them at subtoxic mass to a few volunteers has been suggested.
  • Radiopharmaceuticals are special in the sense that the chemical carrier might be genotoxic, whereas it is well established that ionizing radiation coupled to the molecule is genotoxic, and that the mechanism that causes cancer is similar to certain genotoxic chemicals.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Pharmacol. 2003 Sep;59(5-6):357-66 [12937873.001]
  • [Cites] Toxicol Sci. 2005 Aug;86(2):226-30 [15829616.001]
  • [Cites] Risk Anal. 2000 Apr;20(2):163-72 [10859777.001]
  • [Cites] Drug Metab Rev. 1998 May;30(2):359-404 [9606609.001]
  • [Cites] J Org Chem. 2002 May 31;67(11):3687-92 [12027681.001]
  • [Cites] Regul Toxicol Pharmacol. 2006 Apr;44(3):198-211 [16412543.001]
  • [Cites] Eur J Nucl Med. 1985;11(5):166-70 [2998797.001]
  • [Cites] Eur J Nucl Med. 2001 Apr;28(4):541-61 [11357507.001]
  • [Cites] Mutat Res. 1991 Jun;248(2):213-6 [2046679.001]
  • (PMID = 17457579.001).
  • [ISSN] 0031-6970
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radioisotopes; 0 / Radiopharmaceuticals
  •  go-up   go-down


48. Oono Y, Fu K, Nakamura H, Iriguchi Y, Yamamura A, Kishi D, Oda J, Ikematsu H, Mizutani M, Takayanagi S, Tomino Y: Narrowband imaging colonoscopy with a transparent hood for diagnosis of a squamous cell carcinoma in situ in the anal canal. Endoscopy; 2010;42 Suppl 2:E183-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Narrowband imaging colonoscopy with a transparent hood for diagnosis of a squamous cell carcinoma in situ in the anal canal.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Colonoscopy / methods


49. Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, Kodner IJ, Malayapa RS, Mutch MG, Parikh P, Picus J, Tan BR: Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):428-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
  • PURPOSE: To evaluate the factors associated with disease control and morbidity after radiotherapy for anal carcinoma.
  • METHODS AND MATERIALS: Between 1975 and 2005, 194 patients with localized epidermoid anal carcinoma underwent radiotherapy.
  • Univariate analysis for UNED survival showed a strong association with the T and N stage (5-year UNED rate, 88.5% +/- 3.4% for those with Stage T1-T2N0; 70.1% +/- 4.2% for Stage T3N0; and 52.7% +/- 6.6% for Stage III; p > .001) and mobility on palpation (5-year UNED rate, 89.2% +/- 4.6% for those with mobile tumors vs. 59.3% +/- 6.1% for those with tethered/fixed tumor; p > .001).
  • The radiotherapy factors associated with Grade 3 or greater late morbidity included anorectal morbidity with tumor dose (29% with a dose > or =55 Gy vs. 9% otherwise), small bowel injury with technique (9% with anteroposterior-posteroanterior supine vs. 0.7% with multiple fields prone), and bone injury with femoral head dose (9% with a dose of > or =44 Gy vs. 0.7% otherwise).
  • Of the 194 patients, 56 had 68 additional malignancies, mainly either antedating the anal cancer or outside the radiation fields.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy


50. Kim CW, Kim JH, Yu CS, Shin US, Park JS, Jung KY, Kim TW, Yoon SN, Lim SB, Kim JC: Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery. Int J Radiat Oncol Biol Phys; 2010 Sep 1;78(1):156-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery.
  • PURPOSE: The aim of the present study was to compare the influence of preoperative chemoradiotherapy (CRT) with postoperative CRT on the incidence and types of postoperative complications in rectal cancer patients who underwent sphincter-saving resection.
  • RESULTS: There was no between-group difference in age, gender, or cancer stage.
  • In the pre-CRT group, the mean level of anastomosis from the anal verge was lower (3.5 +/- 1.4 cm vs. 4.3 +/- 1.7 cm, p < 0.001) and the rate of T4 lesion and temporary diverting ileostomy was higher than in the post-CRT group.
  • [MeSH-major] Adenocarcinoma. Anal Canal / surgery. Neoadjuvant Therapy / methods. Postoperative Complications / etiology. Rectal Neoplasms

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20106604.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


51. Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y: CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol; 2009;41(2):259-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population.
  • Genetic differences in the metabolism of xenobiotics have recently been suggested as modifiers of individual susceptibility to bladder cancer (BC).
  • We investigated the distribution of these polymorphisms in 135 BC patients and in 128 age and sex-matched cancer-free controls.
  • Genotype and allele frequencies and their associations with BC risk, demographic factors, smoking status, and tumor stage were investigated.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2006 Mar 13;25(11):1679-91 [16550168.001]
  • [Cites] Cancer Invest. 2006 Feb;24(1):41-5 [16466991.001]
  • [Cites] Urol Oncol. 2008 Jan-Feb;26(1):1-8 [18190823.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):339-44 [16005379.001]
  • [Cites] Pain Med. 2004 Mar;5(1):81-93 [14996240.001]
  • [Cites] Otol Neurotol. 2005 May;26(3):392-7 [15891640.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):483-9 [12663508.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Oct 1;154(1):81-5 [15381379.001]
  • [Cites] Arch Toxicol. 2001 Oct;75(8):459-64 [11757669.001]
  • [Cites] Anal Biochem. 1996 Apr 5;236(1):184-6 [8619490.001]
  • [Cites] IARC Sci Publ. 1999;(148):173-95 [10493258.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Int J Urol. 2008 Mar;15(3):216-21 [18304215.001]
  • [Cites] Cell Biochem Funct. 2005 Jul-Aug;23(4):267-72 [15473001.001]
  • [Cites] Am J Otolaryngol. 2004 Sep-Oct;25(5):318-22 [15334395.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2400-8 [16240451.001]
  • [Cites] BMC Cancer. 2006 Oct 06;6:239 [17026750.001]
  • [Cites] Int Urol Nephrol. 2007;39(4):1043-8 [17340208.001]
  • [Cites] Cancer Lett. 2003 Dec 30;202(2):193-9 [14643449.001]
  • [Cites] Cancer Lett. 2004 Aug 10;211(2):199-207 [15219943.001]
  • [Cites] Mol Psychiatry. 2000 Jul;5(4):410-7 [10889552.001]
  • [Cites] Mutat Res. 2001 Oct 1;482(1-2):21-6 [11535245.001]
  • [Cites] Physiol Res. 1999;48(6):465-71 [10783912.001]
  • [Cites] Pharmacogenetics. 2001 Jul;11(5):429-35 [11470995.001]
  • [Cites] J Occup Health. 2004 Nov;46(6):440-7 [15613766.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Feb;125(1):1-4 [11297759.001]
  • [Cites] Carcinogenesis. 2004 May;25(5):729-34 [14688016.001]
  • [Cites] Arch Biochem Biophys. 1997 Sep 1;345(1):32-8 [9281308.001]
  • [Cites] Urology. 2005 Jan;65(1):70-5 [15667866.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 1;156(1):68-73 [15588859.001]
  • (PMID = 18690546.001).
  • [ISSN] 1573-2584
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 1.14.14.1 / CYP1A2 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1A2; EC 1.14.14.1 / Cytochrome P-450 CYP2D6; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


52. Yun HR, Lee LJ, Park JH, Cho YK, Cho YB, Lee WY, Kim HC, Chun HK, Yun SH: Local recurrence after curative resection in patients with colon and rectal cancers. Int J Colorectal Dis; 2008 Nov;23(11):1081-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: There are a range of rates and a number of prognostic factors associated with the local recurrence of colorectal cancer after curative resection.
  • MATERIALS AND METHODS: A retrospective review of 1,838 patients who underwent curative resection of non-metastatic colorectal cancer was conducted.
  • RESULTS: There were 994 patients with colon cancer and 844 patients with rectal cancer.
  • With respect to colon cancer, the local recurrence rate was 6.1% (61 patients).
  • With respect to rectal cancer, 95 patients had a local recurrence (11.3%), the rate of which was statistically greater than the local recurrence rate for colon cancer (p < 0.001).
  • In patients with colon and rectal cancer, the pathologic T stage (p = 0.044 and p = 0.034, respectively), pathologic N stage (p = 0.001 and p < 0.001, respectively), and lymphovascular invasion (p = 0.013 and p = 0.004, respectively) were adverse risk factors for local recurrence.
  • The level of the anastomosis from the anal verge was an additional prognostic factor (p = 0.007) in patients with rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1981 Feb;152(2):131-6 [7209752.001]
  • [Cites] Br J Surg. 1984 Jan;71(1):12-6 [6689962.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):55-9 [9208961.001]
  • [Cites] J Am Coll Surg. 2002 Jul;195(1):33-40 [12113543.001]
  • [Cites] Br J Surg. 2007 Dec;94(12):1548-54 [17668888.001]
  • [Cites] Br J Surg. 2006 Jul;93(7):866-71 [16622901.001]
  • [Cites] Cancer. 1980 Jun 15;45(12):2969-74 [7388740.001]
  • [Cites] Br J Surg. 1987 May;74(5):370-2 [3594126.001]
  • [Cites] World J Surg. 2008 Jun;32(6):1124-9 [18259805.001]
  • [Cites] Br J Surg. 2007 Apr;94(4):491-9 [17262751.001]
  • [Cites] Dis Colon Rectum. 2000 Apr;43(4):492-8 [10789744.001]
  • [Cites] Dis Colon Rectum. 2001 Jul;44(7):947-54 [11496074.001]
  • [Cites] Semin Surg Oncol. 1993 Jan-Feb;9(1):33-8 [8356383.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):730-2 [11087635.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):174-82 [8129488.001]
  • [Cites] Dis Colon Rectum. 1985 Jun;28(6):413-5 [2988881.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1597-602 [15937624.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1029-34 [12195186.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):725-9 [11087634.001]
  • [Cites] Int J Colorectal Dis. 1991 Feb;6(1):17-23 [2033347.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):659-63 [6478151.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]
  • [Cites] Br J Surg. 2001 Sep;88(9):1221-7 [11531871.001]
  • [Cites] Surg Oncol. 1995;4(6):283-93 [8809950.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jan;30(1):12-6 [10770562.001]
  • [Cites] Dis Colon Rectum. 2001 Jun;44(6):815-21 [11391141.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):219-24 [16755173.001]
  • [Cites] Ann Surg. 1982 Aug;196(2):162-9 [7046656.001]
  • [Cites] J Surg Oncol. 2003 Nov;84(3):127-31 [14598355.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1127-33 [9749496.001]
  • [Cites] Cancer. 1976 Jun;37(6):2861-5 [949706.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):80-5 [12513965.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1729-34 [11919228.001]
  • [Cites] Int J Colorectal Dis. 1995;10(3):126-32 [7561427.001]
  • (PMID = 18688621.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Zamboni BA, Yothers G, Choi M, Fuller CD, Dignam JJ, Raich PC, Thomas CR Jr, O'Connell MJ, Wolmark N, Wang SJ: Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol; 2010 May 20;28(15):2544-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.
  • PURPOSE: Colon cancer overall survival (OS) is usually computed from the time of diagnosis.
  • Conditional survival (probability of surviving y additional years given they have survived x years [CS or OS|OS]) is an alternative measure that accounts for elapsed time since diagnosis, providing more relevant prognostic information.
  • We extend the concept of CS to condition on the set of patients alive, recurrence-free, and second primary cancer-free (disease-free survival [OS|DFS]).
  • PATIENTS AND METHODS: Using data from National Surgical Adjuvant Breast and Bowel Project trials C-03 through C-07, 5-year OS|DFS was calculated on patients who were disease free up to 5 years after diagnosis, stratified by age, stage, nodal status, and performance status (PS).
  • RESULTS: For stage II, OS|DFS improved from 87% to 92% at 5 years.
  • For stage III, OS|DFS improved from 69% to 88%.
  • CONCLUSION: Prognosis improves over time for almost all groups of patients with colon cancer, especially those with positive nodes.
  • OS|DFS is a more relevant measure of prognosis for those who have already survived disease free a period of time after diagnosis.
  • [MeSH-minor] Age Factors. Aged. Clinical Trials, Phase III as Topic. Disease-Free Survival. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Middle Aged. Prognosis. Quality Assurance, Health Care / methods. Randomized Controlled Trials as Topic. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Lifetime Data Anal. 2008 Dec;14(4):447-63 [18836831.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2211-9 [11596040.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3035-40 [12915592.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):402-6; discussion 406 [14572960.001]
  • [Cites] Oncologist. 2003;8(6):541-52 [14657533.001]
  • [Cites] Eur J Cancer. 2004 May;40(8):1233-43 [15110888.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):2-6 [8115782.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):237-42 [8625098.001]
  • [Cites] J Clin Epidemiol. 1997 Nov;50(11):1289-96 [9393385.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1097-106 [9749492.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 2;90(23):1810-6 [9839521.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):485-91 [10023719.001]
  • [Cites] Breast Cancer Res Treat. 1998;51(3):239-53 [10068082.001]
  • [Cites] Chest. 1999 Sep;116(3):697-703 [10492274.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8664-70 [16260700.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2059-64 [16648506.001]
  • [Cites] Cancer. 2006 May 15;106(10):2165-70 [16586498.001]
  • [Cites] Oncologist. 2006 Jun;11(6):624-9 [16794241.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1331-43 [17326199.001]
  • [Cites] J Thorac Oncol. 2007 Mar;2(3):180-90 [17410040.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2198-204 [17470851.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1408-13 [17693654.001]
  • [Cites] Gastric Cancer. 2007;10(3):153-8 [17922092.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):203-9 [18329082.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):257-64 [11263506.001]
  • (PMID = 20406942.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA-69974; United States / NCI NIH HHS / CA / U10 CA012027; United States / NCI NIH HHS / CA / U10 CA069651; United States / NCI NIH HHS / CA / U10CA-37377; United States / NCI NIH HHS / CA / U10 CA069974; United States / NCI NIH HHS / CA / U10CA-12027; United States / NCI NIH HHS / CA / U10 CA037377; United States / NCI NIH HHS / CA / U10CA-69651
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2881729
  •  go-up   go-down


54. Shrikhande SV, Saoji RR, Barreto SG, Kakade AC, Waterford SD, Ahire SB, Goliwale FM, Shukla PJ: Outcomes of resection for rectal cancer in India: the impact of the double stapling technique. World J Surg Oncol; 2007;5:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of resection for rectal cancer in India: the impact of the double stapling technique.
  • Data on the double-stapling technique (DST) has been widely published in the West where the incidence of colorectal cancer is high.
  • The mean distance of the tumor from anal verge was 7.6 cm (2.5-15 cm) and 8.0 cm (4-15 cm) in the DST and SST groups, respectively.
  • CONCLUSION: This study, perhaps the first from India, demonstrates the feasibility of the DST in a country where the incidence of colorectal cancer is increasing.
  • The observed improvement of surgical outcomes with DST needs further studies to significantly prove these findings in a population where the tumors at presentation are predominantly Astler Coller Stage B and C.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1983 Feb;26(2):87-90 [6822175.001]
  • [Cites] Surgery. 1980 Nov;88(5):710-4 [7434211.001]
  • [Cites] Am J Surg. 1984 Apr;147(4):524-30 [6711755.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):603-5 [3896372.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Dis Colon Rectum. 1986 Dec;29(12):885-90 [2431844.001]
  • [Cites] Int Surg. 1988 Jan-Mar;73(1):19-22 [3360572.001]
  • [Cites] Br J Surg. 1990 May;77(5):510-2 [2354332.001]
  • [Cites] Dis Colon Rectum. 1991 Apr;34(4):317-22 [2007349.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):308-11 [2021845.001]
  • [Cites] Dis Colon Rectum. 1991 Jun;34(6):495-7 [2036929.001]
  • [Cites] Am Surg. 1992 Apr;58(4):270-2 [1586088.001]
  • [Cites] Br J Surg. 1992 Aug;79(8):836-8 [1393488.001]
  • [Cites] Surg Gynecol Obstet. 1992 Oct;175(4):333-6 [1329243.001]
  • [Cites] World J Surg. 1992 Sep-Oct;16(5):866-71 [1462621.001]
  • [Cites] Br J Surg. 1993 Jul;80(7):924-7 [8369941.001]
  • [Cites] Dis Colon Rectum. 1994 Feb;37(2 Suppl):S35-41 [8313790.001]
  • [Cites] Dis Colon Rectum. 1995 May;38(5):480-6; discussion 486-7 [7736878.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1246-50 [7497834.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):25-9 [9102256.001]
  • [Cites] Br J Surg. 1997 Apr;84(4):525-8 [9112908.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):747-51 [9221846.001]
  • [Cites] Surg Today. 1997;27(8):706-9 [9306583.001]
  • [Cites] Aust N Z J Surg. 1997 Sep;67(9):599-602 [9322694.001]
  • [Cites] Surgery. 1997 Oct;122(4):779-84; discussion 784-5 [9347856.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1118-20 [9718010.001]
  • [Cites] Oncology. 1999 Apr;56(3):193-7 [10202273.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):284-91 [10336809.001]
  • [Cites] Indian J Gastroenterol. 1999 Jul-Sep;18(3):118-21 [10407566.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s79-81 [15655652.001]
  • [Cites] Trop Gastroenterol. 2001 Apr-Jun;22(2):83-6 [11552491.001]
  • [Cites] Br J Surg. 2001 Dec;88(12):1607-12 [11736973.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):983-93 [12507204.001]
  • [Cites] Int J Colorectal Dis. 2003 Nov;18(6):463-9 [14517685.001]
  • [Cites] Surg Today. 2004;34(1):32-9 [14714226.001]
  • [Cites] Br J Surg. 1980 Mar;67(3):198-200 [7362961.001]
  • [Cites] Dis Colon Rectum. 1983 Apr;26(4):231-5 [6839891.001]
  • (PMID = 17374176.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1839092
  • [General-notes] NLM/ Original DateCompleted: 20070726
  •  go-up   go-down


55. Fariña-Sarasqueta A, Gosens MJ, Moerland E, van Lijnschoten I, Lemmens VE, Slooter GD, Rutten HJ, van den Brule AJ: TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Anal Cell Pathol (Amst); 2010;33(1):1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.
  • AIM: Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences.
  • With this study, we aimed to elucidate the role of TS gene polymorphisms genotyping in therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant chemotherapy.
  • PATIENTS AND METHODS: 251 patients diagnosed with stage III colon carcinoma treated with surgery followed by 5-FU based adjuvant therapy were selected.
  • RESULTS: There was a positive association between tumor T stage and the VNTR genotypes (p=0.05).In both univariate and multivariate survival analysis no effects of the studied polymorphisms on survival were found.
  • CONCLUSION: We conclude that the TS VNTR and SNP do not predict response to 5-FU therapy in patients with stage III colon carcinoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Oncol (Dordr). 2011 Aug;34(4):407-8
  • (PMID = 20966539.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4605551
  •  go-up   go-down


56. Bock O, Neuse J, Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H: Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol; 2006 Aug;169(2):471-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status.
  • Whereas no correlation was found between the JAK2 status and MMP gene products, there was an evident association with the stage of disease.
  • We conclude that the expression of matrix-modeling genes in cIMF is not influenced by the JAK2 mutation status but is predominantly related to the stage of disease.

  • Genetic Alliance. consumer health - Myelofibrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2006 May;8(2):170-7 [16645202.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):248-58 [16397238.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3374-80 [11071630.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):3491-8 [11207308.001]
  • [Cites] Anal Biochem. 2001 Aug 1;295(1):116-7 [11476553.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):195-204 [11722433.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Methods. 2001 Dec;25(4):409-18 [11846610.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):709-12 [12437648.001]
  • [Cites] Am J Clin Pathol. 2003 Jan;119(1):152-8 [12520711.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Pathol. 2003 Jul;200(4):448-64 [12845612.001]
  • [Cites] Eur J Haematol. 2003 Oct;71(4):276-82 [12950237.001]
  • [Cites] Acta Haematol. 2004;111(3):155-9 [15034237.001]
  • [Cites] Cell Adhes Commun. 1993 Sep;1(2):93-9 [8081879.001]
  • [Cites] Cell. 1998 Feb 6;92(3):391-400 [9476898.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4641-51 [9845530.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2627-36 [10194442.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Dec;287(6):G1227-37 [15284024.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):757-67 [15545316.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] J Pathol. 2005 Apr;205(5):548-57 [15726648.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4508-15 [15705794.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4187-90 [15817681.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):76-82 [15982347.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1128-32 [16079113.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1261-8 [16109602.001]
  • [Cites] J Exp Med. 2005 Sep 5;202(5):663-71 [16147977.001]
  • [Cites] Semin Hematol. 2005 Oct;42(4):248-58 [16210038.001]
  • [Cites] FEBS Lett. 2005 Oct 24;579(25):5487-93 [16213498.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3370-3 [16037387.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):1-8 [15920734.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8520-30 [16293880.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • (PMID = 16877349.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 3.4.24.- / Collagenases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC1780160
  •  go-up   go-down


57. Liney KE, Hagger JA, Tyler CR, Depledge MH, Galloway TS, Jobling S: Health effects in fish of long-term exposure to effluents from wastewater treatment works. Environ Health Perspect; 2006 Apr;114 Suppl 1:81-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early life-stage roach, Rutilus rutilus, were exposed for 300 days to treated wastewater effluent at concentrations of 0, 15.2, 34.8, and 78.7% (with dechlorinated tap water as diluent).
  • Concentrations of treated effluents that induced feminization of male roach, measured as vitellogenin induction and histological alteration to gonads, also caused statistically significant alterations in kidney development (tubule diameter), modulated immune function (differential cell count, total number of thrombocytes), and caused genotoxic damage (micronucleus induction and single-strand breaks in gill and blood cells).

  • MedlinePlus Health Information. consumer health - Hazardous Waste.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Sci Technol. 2003 Mar 15;37(6):1142-9 [12680667.001]
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2003 May;135(1):25-38 [12727547.001]
  • [Cites] Ecotoxicology. 2003 Feb-Aug;12(1-4):345-63 [12739880.001]
  • [Cites] Aquat Toxicol. 2003 May 29;63(4):431-46 [12758007.001]
  • [Cites] Ecotoxicol Environ Saf. 2003 Jul;55(3):300-6 [12798764.001]
  • [Cites] Environ Toxicol Chem. 2003 Jul;22(7):1507-16 [12836975.001]
  • [Cites] Environ Health Perspect. 2003 Oct;111(13):1601-7 [14551037.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2004 Jan-Feb;7(1):1-24 [14681080.001]
  • [Cites] Aquat Toxicol. 2004 Mar 30;67(1):45-56 [15019250.001]
  • [Cites] Toxicology. 2004 Mar 15;196(3):237-45 [15036750.001]
  • [Cites] Environ Sci Technol. 2001 Feb 1;35(3):462-70 [11351715.001]
  • [Cites] Aquat Toxicol. 2000 Nov;51(1):69-78 [10998500.001]
  • [Cites] Aquat Toxicol. 2001 Feb;51(4):431-41 [11090901.001]
  • [Cites] Dis Aquat Organ. 2001 Apr 10;44(3):161-70 [11383563.001]
  • [Cites] Vet Immunol Immunopathol. 1991 Sep;29(3-4):339-51 [1949594.001]
  • [Cites] Fundam Appl Toxicol. 1994 Jan;22(1):1-7 [7907300.001]
  • [Cites] Chem Res Toxicol. 1994 Jan-Feb;7(1):23-8 [8155821.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5515-7 [7923187.001]
  • [Cites] Mutat Res. 1994 Dec 1;311(2):191-7 [7526183.001]
  • [Cites] Environ Health Perspect. 1995 Jun;103(6):582-7 [7556011.001]
  • [Cites] Mutat Res. 1995 Nov;345(1-2):87-95 [8524359.001]
  • [Cites] Environ Mol Mutagen. 1996;27(2):116-39 [8603665.001]
  • [Cites] Nature. 1996 Nov 21;384(6606):221-2 [8918871.001]
  • [Cites] Environ Health Perspect. 1996 Oct;104(10):1096-101 [8930552.001]
  • [Cites] Toxicol Appl Pharmacol. 1997 Mar;143(1):205-12 [9073609.001]
  • [Cites] Mutat Res. 1997 Apr 24;390(1-2):21-31 [9150749.001]
  • [Cites] Crit Rev Toxicol. 1998 Jul;28(4):319-61 [9711432.001]
  • [Cites] J Endocrinol. 1998 Sep;158(3):327-39 [9846162.001]
  • [Cites] J AOAC Int. 1998 Nov-Dec;81(6):1209-16 [9850583.001]
  • [Cites] Sci Total Environ. 1999 Jan 12;225(1-2):81-90 [10028705.001]
  • [Cites] Mutat Res. 1999 Mar 8;424(1-2):107-15 [10064854.001]
  • [Cites] Environ Health Perspect. 1999 May;107(5):385-90 [10210694.001]
  • [Cites] Environ Health Perspect. 2005 Oct;113(10):1299-307 [16203238.001]
  • [Cites] Environ Toxicol Chem. 2001 Jun;20(6):1276-90 [11392137.001]
  • [Cites] Environ Sci Technol. 2001 Jun 15;35(12):2476-81 [11432551.001]
  • [Cites] Ambio. 2001 May;30(3):122-6 [11436658.001]
  • [Cites] Arch Environ Contam Toxicol. 2001 Apr;40(3):392-8 [11443371.001]
  • [Cites] Aquat Toxicol. 2001 Sep;54(1-2):101-12 [11451429.001]
  • [Cites] Mar Environ Res. 2000 Jul-Dec;50(1-5):283-7 [11460705.001]
  • [Cites] Environ Sci Technol. 2001 Jul 15;35(14):2909-16 [11478242.001]
  • [Cites] ILAR J. 2001;42(4):285-91 [11581520.001]
  • [Cites] Environ Toxicol Chem. 2001 Oct;20(10):2133-41 [11596741.001]
  • [Cites] Environ Toxicol Chem. 2001 Oct;20(10):2268-75 [11596760.001]
  • [Cites] Biol Reprod. 2002 Feb;66(2):272-81 [11804939.001]
  • [Cites] Neurotoxicol Teratol. 2002 Jan-Feb;24(1):71-9 [11836073.001]
  • [Cites] Environ Toxicol Chem. 2002 Mar;21(3):507-14 [11878463.001]
  • [Cites] Comp Med. 2001 Feb;51(1):56-9 [11926303.001]
  • [Cites] Environ Sci Technol. 2002 Apr 15;36(8):1751-6 [11993873.001]
  • [Cites] Environ Sci Technol. 2002 Jun 1;36(11):2311-21 [12075783.001]
  • [Cites] Mar Environ Res. 2004 Aug-Dec;58(2-5):489-94 [15178071.001]
  • [Cites] Toxicol Lett. 2004 Jun 15;151(1):113-34 [15177647.001]
  • [Cites] Mutat Res. 1976 Dec;41(2-3):321-32 [796719.001]
  • [Cites] CRC Crit Rev Toxicol. 1977 May;5(1):67-101 [17515.001]
  • [Cites] Exp Cell Res. 1988 Mar;175(1):184-91 [3345800.001]
  • [Cites] Toxicol Pathol. 1990;18(1 Pt 1):32-8 [2362986.001]
  • [Cites] Anal Biochem. 1990 Jul;188(1):155-8 [2221356.001]
  • [Cites] Comp Biochem Physiol C. 1991;100(1-2):133-6 [1677844.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16380-6 [1653233.001]
  • [Cites] Appl Environ Microbiol. 1991 Jul;57(7):2101-3 [1892400.001]
  • [Cites] Mutat Res. 1999 Dec 16;431(1):105-21 [10656490.001]
  • [Cites] Crit Rev Toxicol. 2000 Jan;30(1):71-133 [10680769.001]
  • [Cites] Endocr Rev. 2000 Feb;21(1):40-54 [10696569.001]
  • [Cites] J Chromatogr A. 2000 Mar 3;872(1-2):309-14 [10749507.001]
  • [Cites] Mutat Res. 2000 Oct 31;470(2):221-8 [11027977.001]
  • [Cites] Aquat Toxicol. 2001 Apr;52(2):157-76 [11164537.001]
  • [Cites] Mutat Res. 2001 Apr 5;491(1-2):39-44 [11287296.001]
  • [Cites] Mutagenesis. 2002 Jul;17(4):345-52 [12110632.001]
  • [Cites] Environ Health Perspect. 2002 Sep;110(9):917-21 [12204827.001]
  • [Cites] Environ Pollut. 2002;120(3):735-8 [12442797.001]
  • [Cites] Mar Environ Res. 2003 Mar;55(2):137-59 [12502035.001]
  • [Cites] Ecotoxicology. 2002 Dec;11(6):423-34 [12521139.001]
  • [Cites] FEBS Lett. 2003 Jan 30;535(1-3):153-8 [12560095.001]
  • [Cites] Environ Mol Mutagen. 2003;41(2):85-91 [12605376.001]
  • [Cites] Environ Sci Technol. 2003 Feb 1;37(3):462-7 [12630459.001]
  • (PMID = 16818251.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Hazardous Waste; 0 / Industrial Waste; 0 / Steroids; 0 / Vitellogenins; 0 / Water Pollutants, Chemical
  • [Other-IDs] NLM/ PMC1874182
  •  go-up   go-down


58. Goel A, Littenberg B, Burack RC: The association between the pre-diagnosis mammography screening interval and advanced breast cancer. Breast Cancer Res Treat; 2007 May;102(3):339-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between the pre-diagnosis mammography screening interval and advanced breast cancer.
  • BACKGROUND: While screening has been demonstrated to reduce breast cancer mortality, the optimal screening interval is unknown.
  • We designed a study to determine the risk of an advanced breast cancer diagnosis by varying the interval between mammograms.
  • METHODS: We reviewed a single state's mammography records of women diagnosed with breast cancer between 1994 and 2002.
  • The pre-diagnosis screening interval was the number of days between the last two eligible mammograms preceding a cancer diagnosis.
  • Advanced breast cancer was >or=stage IIB, tumor size >2 cm, or >or=one lymph node with cancer.
  • RESULTS: The probability of an advanced breast cancer diagnosis did not differ between women with an annual pre-diagnosis screening interval and women with a biennial interval (21.1% vs. 23.7%, P=0.262).
  • A longer pre-diagnosis screening interval was weakly associated with advanced breast cancer (21.8% for intervals 0.75-2.49 years vs. 26.8% for longer intervals, P=0.070).
  • In multivariate analysis, we found an interaction between the pre-diagnosis screening interval and age.
  • Among women 50 years or older, the risk of an advanced breast cancer diagnosis risk was higher for women with a pre-diagnosis screening interval exceeding 2.49 years compared to women with shorter screening intervals (OR 1.99 [1.02-3.90]).
  • CONCLUSIONS: We found no difference in advanced breast cancer rates between women using mammography annually or biennially.
  • Among women 50 years or older, the advanced breast cancer rate increased when the pre-diagnosis screening interval exceeded 2.49 years.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Jun;174(6):1769-77 [10845521.001]
  • [Cites] Radiology. 2000 Dec;217(3):832-40 [11110951.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jul;68(1):33-43 [11678307.001]
  • [Cites] Arch AIDS Res. 1996;10(1-2):73-82 [12320022.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2160-8 [12001112.001]
  • [Cites] Ann Intern Med. 2002 Sep 3;137(5 Part 1):344-6 [12204019.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1784-92 [16251534.001]
  • [Cites] CA Cancer J Clin. 2003 May-Jun;53(3):141-69 [12809408.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3244-8 [12947058.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 1;96(17):1311-21 [15339969.001]
  • [Cites] CA Cancer J Clin. 1997 May-Jun;47(3):150-3 [9152172.001]
  • [Cites] J Natl Cancer Inst. 2004 Dec 15;96(24):1832-9 [15601639.001]
  • [Cites] Med Sci Monit. 2005 Mar;11(3):RA86-93 [15735580.001]
  • [Cites] Anal Quant Cytol Histol. 2002 Dec;24(6):345-54 [12508694.001]
  • (PMID = 16927175.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA101493; United States / NCI NIH HHS / CA / 5R03CA101493; United States / NCI NIH HHS / CA / R03 CA101493-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS14929; NLM/ PMC1839955
  •  go-up   go-down


59. Elgaili EM, Abuidris DO, Rahman M, Michalek AM, Mohammed SI: Breast cancer burden in central Sudan. Int J Womens Health; 2010;2:77-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer burden in central Sudan.
  • Breast cancer is a worldwide disease resulting in many deaths.
  • Although breast cancer incidence is lower in Sub-Saharan African countries than in developed countries, African women are more likely than women in the developed world to be diagnosed at later stages of the disease and, thus, are more likely to die from it.
  • This descriptive study was undertaken to shed light on the type, stage and age distribution of breast cancer at diagnosis in women living in central Sudan encompassing al-Gezira, Blue Nile, White Nile, and Sennar States.
  • Cases comprised 1255 women from central Sudan diagnosed with breast cancer and referred to and treated at Institute of Nuclear Medicine, Molecular Biology, and Oncology, from January 1999 to December 2006.
  • Invasive ductal carcinoma was the most common pathology (82%) and women presenting with stage III or higher tumors that had already metastasized, while ductal carcinoma in situ was the least prevalent (0.5%) finding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21072300.001).
  • [ISSN] 1179-1411
  • [Journal-full-title] International journal of women's health
  • [ISO-abbreviation] Int J Womens Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2971742
  • [Keywords] NOTNLM ; Africa / epidemiology / estrogen receptor / female breast cancer / progesterone receptor
  •  go-up   go-down


60. Kommoss S, Schmidt D, Kommoss F, Hedderich J, Harter P, Pfisterer J, du Bois A: Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Virchows Arch; 2009 Mar;454(3):249-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).
  • While there is no doubt that histologic grading is applicable in early stage ovarian carcinoma, it is still in controversial discussion concerning advanced stage ovarian carcinoma.
  • It was the aim of this study to assess the three most widely used grading systems for ovarian carcinoma in terms of prognostic significance, concordance rates, and reproducibility in a large number of advanced stage ovarian carcinomas of all types after standardized chemotherapy.
  • Representative hematoxylin and eosin slides from 334 cases of stage IIB-IV ovarian carcinoma (prospective randomized, multi-center, phase III study) were used.
  • Grading of advanced stage ovarian carcinomas was of no value for estimation of prognosis in this homogeneously treated patient group.
  • [MeSH-minor] Aged. Clinical Trials, Phase III as Topic. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Prognosis. Randomized Controlled Trials as Topic. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2008 Feb;52(3):393-5 [18081817.001]
  • [Cites] Cancer. 1980 Feb;45(3):572-81 [7353206.001]
  • [Cites] Obstet Gynecol. 1982 May;59(5):576-82 [7070728.001]
  • [Cites] APMIS. 1991 Apr;99(4):353-8 [2036219.001]
  • [Cites] Gynecol Oncol. 1984 Jan;17(1):117-23 [6693048.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1168-74 [17667538.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):447-52 [12798710.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • [Cites] Anal Quant Cytol Histol. 1986 Dec;8(4):354-7 [3814303.001]
  • [Cites] Histopathology. 2000 May;36(5):433-8 [10792484.001]
  • [Cites] Lancet. 2001 Jan 20;357(9251):176-82 [11213094.001]
  • [Cites] Int J Gynecol Pathol. 2000 Oct;19(4):348-53 [11109164.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):67-71 [16516280.001]
  • [Cites] Acta Obstet Gynecol Scand. 1971;50(1):1-7 [5558593.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(3):197-211 [2846458.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):175-81 [18317226.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):496-504 [15087669.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):52-6 [12496698.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(2):147-55 [2714932.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] J Obstet Gynaecol Res. 2001 Dec;27(6):313-8 [11794816.001]
  • (PMID = 19172293.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


61. Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao MS, Vogel WF: Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer; 2007 Mar 12;96(5):808-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma.
  • We sought to determine expression levels of DDRs in human lung cancer, investigate prognostic determinates, and determine the prevalence of recently reported mutations in these receptor tyrosine kinases.
  • Tumour samples from 146 non-small cell lung carcinoma (NSCLC) patients were analysed for relative expression of DDR1 and DDR2 using quantitative real-time PCR (qRT-PCR).
  • Multivariate analysis revealed DDR1 is an independent favourable predictor for prognosis independent of tumour differentiation, stage, histology, and patient age.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Receptor Protein-Tyrosine Kinases / biosynthesis. Receptors, Mitogen / biosynthesis
  • [MeSH-minor] Animals. Cell Line, Tumor. DNA Mutational Analysis. Humans. Male. Mice. Mutation. Polymorphism, Genetic. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R197-205 [16244318.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1928-36 [16424224.001]
  • [Cites] Am J Pathol. 2006 Mar;168(3):866-77 [16507902.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):239-48 [16234985.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1108-16 [16626936.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5330-7 [16707459.001]
  • [Cites] Lancet Oncol. 2006 Jun;7(6):499-507 [16750500.001]
  • [Cites] Clin Lung Cancer. 2006 May;7 Suppl 4:S138-44 [16764754.001]
  • [Cites] Nucleic Acids Res. 2006;34(12):e85 [16840529.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Aug 15;174(4):420-7 [16690978.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1400-9 [11126911.001]
  • [Cites] J Clin Invest. 2001 Mar;107(6):727-35 [11254672.001]
  • [Cites] Circ Res. 2002 Jun 14;90(11):1147-9 [12065315.001]
  • [Cites] Int J Cancer. 2003 Jan 20;103(3):344-51 [12471617.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1289-301 [12628922.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):521-9 [12765478.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1575-85 [15111304.001]
  • [Cites] Nephron Exp Nephrol. 2004;97(2):e62-70 [15218324.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4427-36 [15240533.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Am J Pathol. 1993 Feb;142(2):413-23 [8382008.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5677-81 [8390675.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):569-75 [7845682.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):609-18 [7845687.001]
  • [Cites] Pathobiology. 1997;65(4):195-203 [9396043.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7591-5 [16140923.001]
  • (PMID = 17299390.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Mitogen; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / discoidin receptor
  • [Other-IDs] NLM/ PMC2360060
  •  go-up   go-down


62. Eidemüller M, Ostroumova E, Krestinina L, Epiphanova S, Akleyev A, Jacob P: Comparison of mortality and incidence solid cancer risk after radiation exposure in the Techa River Cohort. Radiat Environ Biophys; 2010 Aug;49(3):477-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of mortality and incidence solid cancer risk after radiation exposure in the Techa River Cohort.
  • In the present paper, analysis of solid cancer mortality and incidence risk after radiation exposure in the Techa River Cohort in the Southern Urals region of Russia is described.
  • The analysis was performed by means of the biologically based two-stage clonal expansion (TSCE) model and conventional excess relative risk models.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2007 Feb;28(2):479-87 [16973671.001]
  • [Cites] Occup Environ Med. 2005 Jul;62(7):465-72 [15961623.001]
  • [Cites] Mutat Res. 2006 May 11;597(1-2):87-97 [16417911.001]
  • [Cites] Int J Radiat Biol. 1989 Jan;55(1):85-92 [2562980.001]
  • [Cites] Cancer Causes Control. 2008 Apr;19(3):317-28 [18058248.001]
  • [Cites] Health Phys. 2001 Oct;81(4):395-405 [11569634.001]
  • [Cites] Radiat Res. 2007 Apr;167(4):396-416 [17388693.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):309-22 [9498895.001]
  • [Cites] Mutat Res. 2006 May 11;597(1-2):73-7 [16417909.001]
  • [Cites] Radiat Environ Biophys. 2002 Mar;41(1):45-8 [12014408.001]
  • [Cites] Radiat Environ Biophys. 1996 May;35(2):127-9 [8792461.001]
  • [Cites] Radiat Res. 2007 Jul;168(1):1-64 [17722996.001]
  • [Cites] Radiat Res. 2004 Oct;162(4):377-89 [15447045.001]
  • [Cites] Mutat Res. 2009 Oct 2;669(1-2):48-55 [19416732.001]
  • [Cites] Sci Total Environ. 1994 Mar 1;142(1-2):1-8 [8178126.001]
  • [Cites] Health Phys. 2000 Jul;79(1):24-35 [10855775.001]
  • [Cites] Radiat Environ Biophys. 2008 Jul;47(3):375-88 [18481074.001]
  • [Cites] Radiat Res. 2003 Oct;160(4):381-407 [12968934.001]
  • [Cites] Radiat Environ Biophys. 2007 Nov;46(4):383-94 [17562061.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16226-31 [12446840.001]
  • [Cites] Radiat Res. 2003 May;159(5):581-96 [12710869.001]
  • [Cites] Radiat Environ Biophys. 2005 Oct;44(2):119-29 [16136318.001]
  • [Cites] Radiat Res. 2003 May;159(5):567-80 [12710868.001]
  • [Cites] Radiat Environ Biophys. 2008 Nov;47(4):469-79 [18648838.001]
  • [Cites] Int J Epidemiol. 2007 Oct;36(5):1038-46 [17768163.001]
  • [Cites] Radiat Res. 2008 Feb;169(2):138-48 [18220471.001]
  • [Cites] Radiat Res. 2005 Nov;164(5):602-11 [16238437.001]
  • [Cites] Radiat Res. 2005 Nov;164(5):591-601 [16238436.001]
  • [Cites] Radiat Res. 1997 Oct;148(4):348-58 [9339951.001]
  • [Cites] Stat Methods Med Res. 1997 Dec;6(4):305-15 [9447651.001]
  • [Cites] Health Phys. 2000 May;78(5):542-54 [10772028.001]
  • [Cites] Radiat Res. 1999 Oct;152(4):339-51 [10477911.001]
  • [Cites] Risk Anal. 1997 Jun;17(3):391-9 [9232020.001]
  • [Cites] Mutat Res. 2004 Dec 2;568(1):21-32 [15530536.001]
  • [Cites] Radiat Res. 2001 Jul;156(1):78-94 [11418076.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1037-52 [6941039.001]
  • (PMID = 20461395.001).
  • [ISSN] 1432-2099
  • [Journal-full-title] Radiation and environmental biophysics
  • [ISO-abbreviation] Radiat Environ Biophys
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


63. Maw MK, Fujimoto J, Tamaya T: Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumor advancement of ovarian cancers. BMC Cancer; 2009;9:430
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The inhibitor of DNA-binding (ID) has been involved in cell cycle regulation, apoptosis and angiogenesis.
  • RESULTS: ID-1 histoscores and mRNA levels both significantly (p < 0.001) increased in ovarian cancers according to clinical stage, regardless of histopathological type.
  • CONCLUSION: ID-1 increased in ovarian cancer cells during tumor progression.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Sci. 2006 Sep;97(9):861-7 [16805819.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9637-41 [10449746.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):321-9 [17426247.001]
  • [Cites] Br J Cancer. 2007 Nov 19;97(10):1409-15 [18000500.001]
  • [Cites] Br J Cancer. 2008 Nov 18;99(10):1557-63 [19002177.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):670-7 [10537105.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1332-40 [10728695.001]
  • [Cites] Nature. 2001 Feb 22;409(6823):1067-70 [11234019.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7812-6 [11427735.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2569-77 [11745191.001]
  • [Cites] Oncogene. 2001 Dec 20;20(58):8317-25 [11840324.001]
  • [Cites] Oncogene. 2001 Dec 20;20(58):8334-41 [11840326.001]
  • [Cites] J Urol. 2002 Jun;167(6):2598-602 [11992094.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):721-5 [12016143.001]
  • [Cites] Cancer Biol Ther. 2002 Mar-Apr;1(2):91-6 [12170780.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):473-83 [12498716.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):779-85 [12576450.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):525-30 [12842081.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13543-8 [14578451.001]
  • [Cites] Carcinogenesis. 2004 Jun;25(6):881-7 [14742319.001]
  • [Cites] Apoptosis. 2004 May;9(3):279-89 [15258459.001]
  • [Cites] Trends Mol Med. 2004 Aug;10(8):387-92 [15310459.001]
  • [Cites] Arch Pathol Lab Med. 1985 Aug;109(8):716-21 [3893381.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):815-22 [10487839.001]
  • [Cites] J Virol. 2004 Dec;78(24):13470-8 [15564458.001]
  • [Cites] Oncol Rep. 2005 May;13(5):983-8 [15809768.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):603-14 [16034366.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1668-76 [15905202.001]
  • [Cites] Cancer Sci. 2005 Nov;96(11):784-90 [16271072.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1356-63 [16184548.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):2072-81 [16287090.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):931-41 [16575399.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Nucleic Acids Res. 1994 Mar 11;22(5):749-55 [8139914.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6065-8 [7954447.001]
  • [Cites] Cell Growth Differ. 1995 Jul;6(7):837-43 [7547505.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):884-8 [8611421.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):5888-96 [9315646.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2371-81 [9528806.001]
  • [Cites] Trends Cell Biol. 1998 Feb;8(2):58-65 [9695810.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):203-10 [16469432.001]
  • (PMID = 20003244.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / ID1 protein, human; 0 / ID2 protein, human; 0 / Inhibitor of Differentiation Protein 1; 0 / Inhibitor of Differentiation Protein 2; 0 / Inhibitor of Differentiation Proteins; 0 / Neoplasm Proteins; 147785-34-0 / ID3 protein, human
  • [Other-IDs] NLM/ PMC2796680
  •  go-up   go-down


64. Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients. Int Semin Surg Oncol; 2007 Sep 20;4:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients.
  • METHODS: patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3-4/anyN, or anyT/N1-2; ECOG Performance Status 0-2.
  • Twenty-eight patients were stage II and 19 stage III.
  • 2 patients experienced a severe grade 4 gastrointestinal toxicity (a colo-vaginal fistula and an intestinal obstruction, both successfully treated).
  • CONCLUSION: bifractionated accelerated RT administered in the preoperative setting to patients bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly infectious) is acceptably low and long-term survivals are achievable.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):90-4; discussion 94-5 [8311145.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):157-67 [9488510.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Ann Surg. 1994 Nov;220(5):676-82 [7979617.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):964-8 [8813788.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):67-73 [7826163.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):757-61 [1643999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):593-8 [6735750.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):387-92 [1587760.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Clin Radiol. 1971 Apr;22(2):145-55 [5575251.001]
  • (PMID = 17883838.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2063497
  •  go-up   go-down


65. Salerno GV, Daniels IR, Moran BJ, Heald RJ, Thomas K, Brown G: Magnetic resonance imaging prediction of an involved surgical resection margin in low rectal cancer. Dis Colon Rectum; 2009 Apr;52(4):632-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging prediction of an involved surgical resection margin in low rectal cancer.
  • PURPOSE: Low rectal cancers (<5 cm from the anal verge), compared with all others, have greater positive resection margin rates, attributed to mesorectal tapering and higher perforation risk.
  • METHODS: The following features were analyzed by using preoperative magnetic resonance imaging from 101 consecutive patients with low rectal tumors: tumor location (posterior/anterior) and magnetic resonance stage (Stage 1-2, tumor within the intersphincteric plane; Stage 3-4 tumor extending into the intersphincteric plane).
  • Magnetic resonance imaging tumor regression grade was measured where posttreatment magnetic resonance imaging was available and compared with histopathologic findings.
  • Magnetic resonance imaging tumor regression grade strongly predicted for positive resection margins; 11 of 15 patients with little treatment response had positive resection margins, compared with 2 of 15 with >50 percent complete treatment response on magnetic resonance imaging (P < 0.001).
  • CONCLUSION: Significant magnetic resonance imaging positive resection margin predictors are tumor into or beyond the intersphincteric plane and magnetic resonance imaging tumor regression grade.
  • [MeSH-major] Anal Canal / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2010 Mar;53(3):362; author reply 362-3 [20173488.001]
  • (PMID = 19404067.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


66. Wu DH, Shaffer AD, Thompson DM, Yang Z, Magnotta VA, Alam R, Suri J, Yuh WT, Mayr NA: Iterative active deformational methodology for tumor delineation: Evaluation across radiation treatment stage and volume. J Magn Reson Imaging; 2008 Nov;28(5):1188-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iterative active deformational methodology for tumor delineation: Evaluation across radiation treatment stage and volume.
  • PURPOSE: To introduce, implement, and assess an iterative modification to the active deformational image segmentation method as applied to cervical cancer tumors.
  • MATERIALS AND METHODS: A comparison by Jaccard similarity (JS) between this active deformational method and manual segmentation was performed on tumors of various sizes across preradiation, 3 weeks postradiation, and 6 weeks postradiation using a General Linear Mixed Model across 121 studies from 52 patients with Stage IIB-IV cervical cancers.
  • The analysis illustrated a rate of improvement in JS with increasing tumor volume that differed between the preradiation and 6 weeks postradiation stage (P=0.0474).
  • The deformation-based segmentation method appears to demonstrate utility for delineating cervical cancer tumors, particularly in the earliest stages of radiation treatment, where agreement is greatest.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Wiley-Liss, Inc.
  • [Cites] IEEE Trans Med Imaging. 2006 Nov;25(11):1472-82 [17117776.001]
  • [Cites] J Magn Reson Imaging. 2006 Dec;24(6):1316-25 [17058203.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5687-94 [17179104.001]
  • [Cites] Methods Inf Med. 2003;42(1):89-98 [12695800.001]
  • [Cites] Med Image Anal. 2006 Apr;10(2):215-33 [16311065.001]
  • [Cites] Stud Health Technol Inform. 1997;39:369-78 [10168933.001]
  • [Cites] J Magn Reson Imaging. 2005 Jan;21(1):1-11 [15611946.001]
  • [Cites] J Appl Clin Med Phys. 2005 Fall;6(4):106-10 [16421504.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Feb;22(2):189-99 [12715995.001]
  • (PMID = 18972365.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA071906-05; United States / NCI NIH HHS / CA / R01 CA071906; United States / NCI NIH HHS / CA / R01 CA071906-05; United States / NCI NIH HHS / CA / R01CA71906-05
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS63971; NLM/ PMC2720022
  •  go-up   go-down


67. Matsumoto T, Nakamura S, Esaki M, Yada S, Moriyama T, Yanai S, Hirahashi M, Yao T, Iida M: Double-balloon endoscopy depicts diminutive small bowel lesions in gastrointestinal lymphoma. Dig Dis Sci; 2010 Jan;55(1):158-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined 29 patients with primary GI lymphoma by oral and anal DBEs.
  • However, clinical stage was more advanced in patients with the lesions than in those without (P < 0.05).
  • The lesions were more frequently found in T-cell lymphoma (100%) and follicular lymphoma (77%) than in the other types of lymphoma (15%) (P < 0.05).
  • Diminutive small intestinal lesions occur in patients with GI lymphoma, especially in those with follicular lymphoma and T-cell lymphoma.
  • [MeSH-major] Endoscopy, Gastrointestinal. Gastrointestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2005 Jun;37(6):594-6 [15933938.001]
  • [Cites] Gastrointest Endosc. 2001 Feb;53(2):216-20 [11174299.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E86-7 [17440873.001]
  • [Cites] Endoscopy. 2005 Dec;37(12):1174-80 [16329013.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):623-9 [12649111.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:249-57 [13695582.001]
  • [Cites] Histopathology. 2003 Aug;43(2):135-43 [12877728.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Haematologica. 2008 Feb;93(2):201-6 [18223283.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):105-13 [12507894.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E149 [18633862.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E204 [17614049.001]
  • [Cites] Gastrointest Endosc. 2008 Apr;67(4):763-5 [18207144.001]
  • [Cites] Histopathology. 2005 Nov;47(5):467-78 [16241994.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):987-96 [17378908.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):442-52 [8604811.001]
  • [Cites] Am J Pathol. 1992 Jun;140(6):1327-35 [1376556.001]
  • [Cites] Endoscopy. 2008 Apr;40(4):343-6 [18067068.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E347-8 [18273791.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] Endoscopy. 2005 Jan;37(1):66-70 [15657861.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Nov;2(11):1010-6 [15551254.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E26-7 [17285496.001]
  • [Cites] Hum Pathol. 1999 May;30(5):581-7 [10333231.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):1020-9 [7927306.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E339-40 [18273786.001]
  • [Cites] J Gastroenterol. 2004 Aug;39(8):739-46 [15338367.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1139-52 [10235185.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3136-41 [16769982.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4445-51 [8977236.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jul;191(1):175-81 [18562742.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E8-9 [18278712.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):286-94 [10640959.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2740-6 [12860953.001]
  • [Cites] Nature. 2000 May 25;405(6785):417 [10839527.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):691-9 [2665536.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):454-7 [10945490.001]
  • (PMID = 19241169.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Kruijt B, van der Snoek EM, Sterenborg HJ, Amelink A, Robinson DJ: A dedicated applicator for light delivery and monitoring of PDT of intra-anal intraepithelial neoplasia. Photodiagnosis Photodyn Ther; 2010 Mar;7(1):3-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dedicated applicator for light delivery and monitoring of PDT of intra-anal intraepithelial neoplasia.
  • The objective of this study was to develop an applicator for delivery of light and monitoring of photodynamic therapy (PDT) in the anal cavity for treatment of anal intraepithelial neoplasia grade III (AIN III), which can progress to invasive anal cancer.
  • For light delivery and monitoring of PDT, an applicator based on standard anoscopy equipment was developed which facilitates, in addition to a light treatment fiber, fiber optic probes to monitor blood saturation, blood volume, fluorescence and fluence (rate) at two different locations in situ.
  • Patients were given a light dose of 10-17 J cm(-2) at a fluence rate of 45-50 mW cm(-2) based on in situ measured light treatment parameters.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / drug therapy. Carcinoma in Situ / diagnosis. Carcinoma in Situ / drug therapy. Lighting / instrumentation. Photochemotherapy / instrumentation. Photosensitizing Agents / administration & dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20230986.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


69. Hessien MH, El-Sharkawi IM, El-Barbary AA, El-Beltagy DM, Snyder N: Non-invasive index of liver fibrosis induced by alcohol, thioacetamide and Schistosomal infection in mice. BMC Gastroenterol; 2010;10:53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-invasive index of liver fibrosis induced by alcohol, thioacetamide and Schistosomal infection in mice.
  • BACKGROUND: Non invasive approaches will likely be increasing utilized to assess liver fibrosis.
  • This work provides a new non invasive index to predict liver fibrosis induced in mice.
  • The following methods were employed: (i) The METAVIR system was utilized to grade and stage liver inflammation and fibosis;.
  • (ii) Determination of hepatic hydroxyproline and collagen; and (iii) Derivation of a new hepatic fibrosis index from the induced changes, and its prospective validation in a group of 70 mice.
  • These parameters were highly correlated with both the histological stage and the grade.
  • They were combined in a logarithmic formula, which non-invasively scores the severity of liver fibrosis through a range (0 to 2), starting with healthy liver (corresponding to stage 0) to advanced fibrosis (corresponding stage 3).Receiver operating characteristic curves (ROC) for the accuracy of the index to predict the histological stages demonstrated that the areas under the curve (AUC) were 0.954, 0.979 and 0.99 for index values corresponding to histological stages 1, 2 and 3, respectively.
  • Also, the index was correlated with stage and grade, (0.947 and 0.859, respectively).
  • The AUROC was 0.869 and there was good correlation with the stage of fibrosis and grade of inflammation.
  • CONCLUSION: The index fulfils the basic criteria of non-invasive marker of liver fibrosis since it is liver-specific, easy to implement, reliable, and inexpensive.

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • Hazardous Substances Data Bank. THIOACETAMIDE .
  • Hazardous Substances Data Bank. ETHANOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Dec;30(6):1529-30 [10610352.001]
  • [Cites] Hepatology. 2009 Jun;49(6):1821-7 [19291784.001]
  • [Cites] N Engl J Med. 2001 Feb 15;344(7):495-500 [11172192.001]
  • [Cites] Lancet. 2001 Apr 7;357(9262):1069-75 [11297957.001]
  • [Cites] Hum Exp Toxicol. 2001 May;20(5):251-4 [11476157.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):986-92 [12297848.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2614-8 [12385448.001]
  • [Cites] Hepatology. 1997 Dec;26(6):1393-8 [9397976.001]
  • [Cites] Hepatology. 1999 Jan;29(1):14-20 [9862843.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):222-30 [12873819.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):239-44 [12873821.001]
  • [Cites] Hepatology. 2003 Aug;38(2):518-26 [12883497.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Feb;2(1):69-72 [14607650.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Res Exp Med (Berl). 1980;177(3):201-11 [6449727.001]
  • [Cites] Pharmacol Ther. 1985;29(1):129-56 [3914644.001]
  • [Cites] Pharmacol Toxicol. 1987 Mar;60(3):171-4 [3588511.001]
  • [Cites] Exp Pathol. 1988;34(4):229-36 [2853079.001]
  • [Cites] Hepatology. 1996 Aug;24(2):289-93 [8690394.001]
  • [Cites] Arch Biochem Biophys. 1959 May;82(1):70-7 [13650640.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):343-50 [15685546.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):167-74 [15704051.001]
  • [Cites] Alcohol Clin Exp Res. 2006 Aug;30(8):1429-35 [16899047.001]
  • [Cites] J Hepatol. 2007 May;46(5):775-82 [17321634.001]
  • [Cites] Clin Chim Acta. 2007 Jun;381(2):119-23 [17442291.001]
  • [Cites] Rinsho Byori. 2007 Aug;55(8):751-7 [17882797.001]
  • [Cites] Hepatology. 2008 Feb;47(2):455-60 [18038452.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):2033-42 [18339886.001]
  • [Cites] Chest. 2008 May;133(5):1101-6 [18071010.001]
  • [Cites] Anal Biochem. 2000 Oct 1;285(1):16-20 [10998259.001]
  • (PMID = 20515488.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 075T165X8M / Thioacetamide; 3K9958V90M / Ethanol; 9007-34-5 / Collagen; EC 2.3.2.2 / gamma-Glutamyltransferase; GAN16C9B8O / Glutathione; RFM9X3LJ49 / Bilirubin; RMB44WO89X / Hydroxyproline
  • [Other-IDs] NLM/ PMC2894747
  •  go-up   go-down


70. Jiang Y, Ma Y: A fast capillary electrophoresis method for separation and quantification of modified nucleosides in urinary samples. Anal Chem; 2009 Aug 1;81(15):6474-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Modified nucleosides are formed at the post-transcriptional stage by chemical modification of normal nucleosides within the ribonucleic acid (RNA).
  • The elevated levels of modified nucleosides in the urine samples have served as potential cancer biomarkers in many studies.
  • Although different analytical techniques have been reported for determining nucleosides levels, they are practically difficult to use as a routine tool for early cancer screening.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19552424.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nucleosides
  •  go-up   go-down


71. Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson GS, Chen PY, Vicini FA, Wong JW: Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Aug 1;62(5):1297-308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
  • PURPOSE: We analyzed our experience treating localized prostate cancer with image-guided off-line correction with adaptive high-dose radiotherapy (ART) in our Phase II dose escalation study to identify factors predictive of chronic rectal toxicity.
  • MATERIALS AND METHODS: From 1999-2002, 331 patients with clinical stage T1-T3N0M0 prostate cancer were prospectively treated in our Phase II 3D conformal dose escalation ART study to a median dose of 75.6 Gy (range, 63.0-79.2 Gy), minimum dose to confidence limited-planning target volume (cl-PTV) in 1.8 Gy fractions (median isocenter dose = 79.7 Gy).
  • For each case, the rectum (rectal solid) was contoured from the sacroiliac joints or rectosigmoid junction (whichever was higher) to the anal verge or ischial tuberosities (whichever was lower), with a median volume of 81.2 cc.
  • Toxicity was quantified using the National Cancer Institute Common Toxicity Criteria 2.0.
  • Thirty-four patients (crude rate = 10.3%) experienced Grade 2 chronic rectal toxicity at a median interval of 1.1 years.
  • Nine patients (crude rate = 2.7%) experienced Grade > or =3 chronic rectal toxicity (1 was Grade 4) at a median interval of 1.2 years.
  • The 3-year rates of Grade > or =2 and Grade > or =3 chronic rectal toxicity were 20% and 4%, respectively.
  • Acute toxicity predicted for chronic: Acute Grade 2-3 rectal toxicity (p < 0.001) including any acute rectal Grade 2-3 tenesmus (p = 0.02) and pain (p = 0.008) were significant predictors of chronic Grade > or =2 rectal toxicity.
  • Dose-volume histogram predicted for chronic toxicity: Rectal wall absolute and relative V50, V60, V66.6, V70, and V72 and rectal solid relative V60-V72 were significantly associated with chronic Grade > or =2 rectal toxicity both as categorical and continuous variables (t test, linear regression) and when divided into subgroups (chi-square table).
  • The chronic rectal toxicity Grade > or =2 risk was 9%, 18%, and 25% for the rectal wall relative V70 <15%, 25%-40%, and >40% respectively.


72. Lingappa M, Song H, Thompson S, Bruchertseifer F, Morgenstern A, Sgouros G: Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res; 2010 Sep 01;70(17):6815-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.
  • Current treatment for late-stage metastatic breast cancer is largely palliative. alpha-Particles are highly potent, short-range radiation emissions capable of sterilizing individual cells with one to three traversals of the cell nucleus.
  • Efficacy in a rat/neu transgenic mouse model of metastatic mammary carcinoma was investigated.
  • We have shown that the (213)Bi radiolabeled immunoliposomes are effective in treating early-stage micrometastases, giving median survival times similar to those obtained with antibody-mediated delivery of (213)Bi in this animal model.

  • Hazardous Substances Data Bank. BISMUTH, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biother Radiopharm. 2004 Dec;19(6):706-15 [15665617.001]
  • [Cites] Health Phys. 1960 Feb;2:225-38 [13818815.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11631-8 [16357174.001]
  • [Cites] Curr Pharm Des. 2006;12(36):4729-49 [17168775.001]
  • [Cites] Bioconjug Chem. 2007 Nov-Dec;18(6):2061-7 [17935286.001]
  • [Cites] Expert Opin Drug Deliv. 2008 Feb;5(2):189-204 [18248318.001]
  • [Cites] Cancer Biother Radiopharm. 2008 Feb;23(1):74-81 [18298331.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3873-80 [18483272.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6116-24 [18829490.001]
  • [Cites] Cancer Res. 2009 Dec 1;69(23):8941-8 [19920193.001]
  • [Cites] J Nucl Med. 2010 Feb;51(2):311-28 [20080889.001]
  • [Cites] J Nucl Med. 1999 Nov;40(11):1935-46 [10565792.001]
  • [Cites] Pharmacol Rev. 1999 Dec;51(4):691-743 [10581328.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3569-76 [10910070.001]
  • [Cites] Pharm Res. 2002 Mar;19(3):265-9 [11934232.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):253-60 [14960644.001]
  • [Cites] Science. 2004 Mar 19;303(5665):1818-22 [15031496.001]
  • [Cites] Expert Opin Ther Targets. 2004 Aug;8(4):335-53 [15268628.001]
  • [Cites] Bioconjug Chem. 1992 Jul-Aug;3(4):342-5 [1390990.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3765-70 [8339289.001]
  • [Cites] Biochim Biophys Acta. 1994 Feb 23;1190(1):99-107 [8110825.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3352-6 [8012948.001]
  • [Cites] Nucl Med Biol. 1995 Apr;22(3):387-90 [7627155.001]
  • [Cites] J Nucl Med. 1995 Sep;36(9):1639-44 [7658225.001]
  • [Cites] J Leukoc Biol. 1996 Sep;60(3):337-44 [8830790.001]
  • [Cites] Biochemistry. 1997 Jan 7;36(1):66-75 [8993319.001]
  • [Cites] J Nucl Med. 1997 Mar;38(3):489-93 [9074545.001]
  • [Cites] Appl Radiat Isot. 1999 May;50(5):895-904 [10214708.001]
  • [Cites] Int J Pharm. 1999 Oct 15;188(1):87-95 [10528086.001]
  • [Cites] J Biol Chem. 1959 Mar;234(3):466-8 [13641241.001]
  • [Cites] Anal Chem. 2005 Oct 1;77(19):6288-91 [16194090.001]
  • (PMID = 20651254.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113797; United States / NCI NIH HHS / CA / R01 CA113797-04; United States / NCI NIH HHS / CA / R01 CA187037
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoconjugates; 0 / Isothiocyanates; 0 / Liposomes; 0 / Radioisotopes; 142434-84-2 / N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid; 7A314HQM0I / Pentetic Acid; EC 2.7.10.1 / Receptor, ErbB-2; U015TT5I8H / Bismuth
  • [Other-IDs] NLM/ NIHMS248891; NLM/ PMC2977986
  •  go-up   go-down


73. Jelski W, Mroczko B, Szmitkowski M: The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients. Dig Dis Sci; 2010 Oct;55(10):2953-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients.
  • BACKGROUND: The activity of total alcohol dehydrogenase (ADH) and class I isoenzymes is significantly higher in colorectal cancer tissue than in healthy mucosa.
  • The activity of these enzymes in cancer cells is probably reflected in the sera and could thus be helpful for diagnosing colorectal cancer.
  • AIM: The aim of this study was to investigate a potential role of ADH and aldehyde dehydrogenase (ALDH) as tumor markers for colorectal cancer.
  • METHODS: Serum samples were taken from 182 patients with colorectal cancer before treatment and from 160 control subjects.
  • Total ADH activity and class III and IV isoenzymes were measured by photometric, but ALDH activity and ADH I and II by the fluorometric method, with class-specific fluorogenic substrates.
  • RESULTS: There was significant increase in the activity of ADH I isoenzyme and ADH total in the sera of colorectal cancer patients compared to the control.
  • The sensitivity and specificity of ADH I increased with the stage of the carcinoma.
  • CONCLUSION: The results suggest a potential role for ADH I as marker for colorectal cancer.
  • [MeSH-major] Alcohol Dehydrogenase / blood. Aldehyde Dehydrogenase / blood. Biomarkers / blood. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / metabolism. Isoenzymes / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1989 Oct 23;257(1):105-9 [2806555.001]
  • [Cites] Clin Chem. 1993 Nov;39(11 Pt 1):2298-304 [8222224.001]
  • [Cites] Clin Exp Med. 2006 Jun;6(2):89-93 [16820997.001]
  • [Cites] Anal Biochem. 1989 Apr;178(1):57-62 [2729580.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):977-81 [15309886.001]
  • [Cites] Clin Exp Med. 2007 Dec;7(4):154-7 [18188528.001]
  • [Cites] Anal Biochem. 1979 Oct 15;99(1):65-71 [231394.001]
  • [Cites] Dig Dis Sci. 2005 Jun;50(6):1019-24 [15986847.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Aug;16(4):775-810 [12418049.001]
  • [Cites] Digestion. 1996;57(2):105-8 [8785998.001]
  • [Cites] Clin Chem Lab Med. 2008;46(10):1423-8 [18844497.001]
  • [Cites] Clin Chim Acta. 2006 Sep;371(1-2):143-7 [16603145.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):208-12 [17368603.001]
  • [Cites] Alcohol Clin Exp Res. 1996 May;20(3):551-5 [8727253.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Dec;20(9):1569-76 [8986205.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):33-8 [16520929.001]
  • [Cites] Clin Chem Lab Med. 2003 May;41(5):646-51 [12812262.001]
  • [Cites] BMJ. 2000 Feb 12;320(7232):424-7 [10669448.001]
  • (PMID = 20069455.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Isoenzymes; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


74. Shui G, Guan XL, Gopalakrishnan P, Xue Y, Goh JS, Yang H, Wenk MR: Characterization of substrate preference for Slc1p and Cst26p in Saccharomyces cerevisiae using lipidomic approaches and an LPAAT activity assay. PLoS One; 2010;5(8):e11956
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Phosphatidic acid (PA) is a key regulated intermediate and precursor for de novo biosynthesis of all glycerophospholipids.
  • A comprehensive high-performance liquid chromatography-based multi-stage MRM approach (more than 500 MRM transitions) was developed and further applied to quantify individual phospholipids in both strains to confirm these changes.
  • These results were consistent with those from a non-radioactive LPAAT enzymatic assay using C17-LPA and acyl-CoA donors as substrates.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2008 Feb 11;180(3):473-82 [18250201.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2830-5 [18287005.001]
  • [Cites] J Cell Sci. 2008 Aug 15;121(Pt 16):2671-84 [18653539.001]
  • [Cites] J Biol Chem. 2008 Oct 31;283(44):30235-45 [18772128.001]
  • [Cites] J Biol Chem. 2009 Jan 2;284(1):1-5 [18718904.001]
  • [Cites] Cell Metab. 2009 Feb;9(2):165-76 [19187773.001]
  • [Cites] Prog Lipid Res. 1999 Sep-Nov;38(5-6):461-79 [10793891.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):41710-6 [11544256.001]
  • [Cites] Anal Chem. 2002 Mar 1;74(5):941-9 [11924996.001]
  • [Cites] Nat Genet. 2002 May;31(1):21-3 [11967537.001]
  • [Cites] Methods Enzymol. 2002;350:87-96 [12073338.001]
  • [Cites] Expert Opin Ther Targets. 2003 Oct;7(5):643-61 [14498826.001]
  • [Cites] Nature. 2003 Oct 16;425(6959):686-91 [14562095.001]
  • [Cites] Plant Cell Physiol. 2004 May;45(5):503-10 [15169931.001]
  • [Cites] J Bacteriol. 1997 Dec;179(24):7611-6 [9401016.001]
  • [Cites] J Bacteriol. 1999 Mar;181(5):1458-63 [10049376.001]
  • [Cites] Mass Spectrom Rev. 2005 May-Jun;24(3):367-412 [15389848.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jul;4(7):594-610 [16052242.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Aug 25;823(1):26-36 [15990370.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9415-25 [16230405.001]
  • [Cites] J Lipid Res. 2006 Mar;47(3):593-604 [16369050.001]
  • [Cites] J Lipid Res. 2006 Apr;47(4):745-54 [16436371.001]
  • [Cites] Yeast. 2006 Apr 30;23(6):465-77 [16652392.001]
  • [Cites] FASEB J. 2006 Jun;20(8):1152-61 [16770014.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1511-9 [16944535.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2006;7:175-99 [16722806.001]
  • [Cites] J Lipid Res. 2007 Jan;48(1):235-41 [17053274.001]
  • [Cites] J Lipid Res. 2007 Sep;48(9):1976-84 [17565170.001]
  • [Cites] J Biol Chem. 2007 Oct 19;282(42):30845-55 [17675291.001]
  • [Cites] J Biol Chem. 2007 Oct 19;282(42):30562-9 [17726007.001]
  • [Cites] FEBS Lett. 2007 Nov 27;581(28):5511-6 [17996202.001]
  • [Cites] J Biol Chem. 2007 Nov 23;282(47):34288-98 [17890783.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2136-41 [19174513.001]
  • [Cites] Mol Biosyst. 2009 Mar;5(3):276-87 [19225619.001]
  • [Cites] FEBS J. 2009 Nov;276(21):6412-24 [19796168.001]
  • [Cites] Mol Biosyst. 2010 Jun;6(6):1008-17 [20485745.001]
  • [Cites] Int J Neuropsychopharmacol. 2009 Aug;12(7):953-64 [19203412.001]
  • (PMID = 20694142.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Saccharomyces cerevisiae Proteins; EC 2.3.- / Acyltransferases; EC 2.3.- / Cst26 protein, S cerevisiae; EC 2.3.1.52 / 2-acylglycerophosphate acyltransferase; EC 3.6.4.2 / Dyneins; EC 3.6.4.2 / SLC1 protein, S cerevisiae
  • [Other-IDs] NLM/ PMC2915916
  •  go-up   go-down


75. Yu J, Ohuchida K, Nakata K, Mizumoto K, Cui L, Fujita H, Yamaguchi H, Egami T, Kitada H, Tanaka M: LIM only 4 is overexpressed in late stage pancreas cancer. Mol Cancer; 2008;7:93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LIM only 4 is overexpressed in late stage pancreas cancer.
  • BACKGROUND: LIM-only 4 (LMO4), a member of the LIM-only (LMO) subfamily of LIM domain-containing transcription factors, was initially reported to have an oncogenic role in breast cancer.
  • If so, this could result in a better understanding of tumorigenesis in pancreatic cancer.
  • METHODS: We measured LMO4 mRNA levels in cultured cells, pancreatic bulk tissues and microdissected target cells (normal ductal cells; pancreatic intraepithelial neoplasia-1B [PanIN-1B] cells; PanIN-2 cells; invasive ductal carcinoma [IDC] cells; intraductal papillary-mucinous adenoma [IPMA] cells; IPM borderline [IPMB] cells; and invasive and non-invasive IPM carcinoma [IPMC]) by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR).
  • RESULTS: 9 of 14 pancreatic cancer cell lines expressed higher levels of LMO4 mRNA than did the human pancreatic ductal epithelial cell line (HPDE).
  • In bulk tissue samples, expression of LMO4 was higher in pancreatic carcinoma than in intraductal papillary-mucinous neoplasm (IPMN) or non-neoplastic pancreas (p < 0.0001 for both).
  • These results suggested that LMO4 is overexpressed at late stages in carcinogenesis of pancreatic cancer.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Analysis of Variance. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Line, Tumor. Humans. LIM Domain Proteins. Neoplasm Staging. Protein-Serine-Threonine Kinases / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 May 19;88(10):1543-8 [12771919.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):93-7 [12629061.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3215-22 [15126362.001]
  • [Cites] Med Electron Microsc. 2004 Jun;37(2):82-8 [15221649.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 15;88(10):4367-71 [2034676.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1887-93 [1923511.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] EMBO J. 1994 Jul 15;13(14):3329-38 [8045262.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1547-50 [7992857.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jan;12(1):24-31 [7534107.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):38-43 [9425897.001]
  • [Cites] Pancreas. 1998 Apr;16(3):238-42 [9548661.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):263-9 [9665487.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11257-62 [9736723.001]
  • [Cites] Biochim Biophys Acta. 1999 Apr 14;1445(1):148-53 [10209267.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1835-40 [10362809.001]
  • [Cites] Gene. 2005 Jan 3;344:67-77 [15656974.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7659-64 [15897450.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Rocz Akad Med Bialymst. 2005;50:69-72 [16358942.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 19;343(4):1186-90 [16580634.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2920-30 [16331278.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3878-82 [16804974.001]
  • [Cites] Oncogene. 2007 Sep 27;26(44):6431-41 [17452977.001]
  • [Cites] Br J Cancer. 2008 Feb 12;98(3):537-41 [18231110.001]
  • [Cites] Am J Pathol. 2000 Nov;157(5):1623-31 [11073822.001]
  • [Cites] Mamm Genome. 1999 Nov;10(11):1089-94 [10556429.001]
  • [Cites] Pancreatology. 2008;8(6):587-92 [18849640.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14452-7 [11734645.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):7849-56 [11751867.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):1067-72 [12370756.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):125-36 [14505145.001]
  • (PMID = 19099607.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Homeodomain Proteins; 0 / LIM Domain Proteins; 0 / LMO4 protein, human; 0 / RNA, Messenger; 0 / Transcription Factors; EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2628350
  •  go-up   go-down


76. Chen R, Pan S, Duan X, Nelson BH, Sahota RA, de Rham S, Kozarek RA, McIntosh M, Brentnall TA: Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer; 2010 Jun 15;9:149
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia.
  • BACKGROUND: Pancreatic intraepithelial neoplasias (PanINs) are precursors of malignant pancreatic cancer, an ideal stage for early cancer detection.
  • An ELISA assay was developed to evaluate AGR2 levels in 51 pancreatic juice samples and 23 serum samples from patients with pancreatic cancer, pre-malignant lesions (including PanIN3, PanIN2, Intraductal Papillary Mucinous Neoplasms (IPMNs)) and benign disease controls (including chronic pancreatitis).
  • AGR2 levels in the pancreatic juice samples were found significantly elevated in patients with pre-malignant conditions (PanINs and IPMNs) as well as pancreatic cancer compared to control samples (p < or = 0.03).
  • CONCLUSIONS: These results suggest that elevation of AGR2 levels in pancreatic juice occurs in early pancreatic cancer progression and could be further investigated as a potential candidate juice biomarker for early detection of pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Clin Sci (Lond). 2010 Jun;118(12):717-25 [20136634.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Pancreas. 1994 Nov;9(6):741-7 [7846018.001]
  • [Cites] Mech Dev. 1998 Mar;72(1-2):115-30 [9533957.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):523-33 [15684406.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6626-36 [16103885.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1728-34 [16551856.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2066-9 [16609017.001]
  • [Cites] Histol Histopathol. 2007 Jul;22(7):703-8 [17455144.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(3):293-300 [17457305.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Nov;5(10):1034-41 [18053427.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):492-7 [18199544.001]
  • [Cites] EMBO Rep. 2008 May;9(5):429-34 [18451766.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7811-8 [18829536.001]
  • [Cites] Cancer Detect Prev. 2008;32(3):236-50 [18801625.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] PLoS Med. 2009 Apr 7;6(4):e1000046 [19360088.001]
  • [Cites] Electrophoresis. 2009 Apr;30(7):1132-44 [19373808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):6950-5 [19359471.001]
  • [Cites] Histol Histopathol. 2009 Sep;24(9):1121-8 [19609859.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • (PMID = 20550709.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01DK081368; United States / NCI NIH HHS / CA / CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296; United States / NCI NIH HHS / CA / R01CA107209; United States / NCI NIH HHS / CA / K07CA116296; United States / NCI NIH HHS / CA / K25CA137222
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteins; EC 5.3.4.1 / AGR2 protein, human
  • [Other-IDs] NLM/ PMC2893103
  •  go-up   go-down


77. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH: Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection. Surg Endosc; 2009 Aug;23(8):1818-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection.
  • PURPOSE: The aim of this study was to compare the outcomes of laparoscopic surgery with those of open resection in patients with extraperitoneal rectal cancer.
  • METHODS: Five hundred forty-four patients with extraperitoneal rectal cancer who underwent curative resection between 1996 and 2007 were included.
  • Differences were found in preoperative carcinoembryonic antigen (CEA) (LAP group 4.6 ng/ml, OPEN group 7.7 ng/ml, p = 0.001), sphincter preservation (LAP group 82.9%, OPEN group 69.8%, p = 0.001), and mean distance from anal verge (LAP group 4.6 cm, OPEN group 5.2 cm, p = 0.002).
  • Local recurrence and metastasis were similar by stage.
  • CONCLUSIONS: The results of this study show that laparoscopic resection of extraperitoneal rectal cancer was safe and effective.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Feb;25(2):658-60 [20632188.001]
  • [CommentIn] Surg Endosc. 2009 Dec;23(12):2871-3 [19688396.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):126-34 [11884047.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1031-3 [7648142.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1457-62 [15791369.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] J Am Coll Surg. 1997 Aug;185(2):105-13 [9249076.001]
  • [Cites] Colorectal Dis. 2006 Jun;8(5):375-88 [16684081.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005200 [17054246.001]
  • [Cites] J Am Coll Surg. 1995 Oct;181(4):335-46 [7551328.001]
  • [Cites] Lancet. 1990 May 5;335(8697):1055-9 [1691810.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):353-8 [16495700.001]
  • [Cites] Surg Endosc. 2005 Jun;19(6):757-66 [15868256.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):374-9 [11289283.001]
  • [Cites] Br J Surg. 1998 Mar;85(3):355-8 [9529492.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):7-13 [11961595.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):284-91 [10336809.001]
  • [Cites] Surgery. 1998 Oct;124(4):612-7; discussion 617-8 [9780979.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1110 [8869318.001]
  • [Cites] Br J Surg. 2003 Apr;90(4):445-51 [12673746.001]
  • [Cites] Surg Endosc. 2005 Nov;19(11):1468-74 [16222464.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):308-11 [2021845.001]
  • [Cites] Surg Endosc. 2005 Nov;19(11):1460-7 [16206013.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):315-21 [11289275.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1224-6 [7953369.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2224-31 [16228823.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):413-24 [16450220.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • (PMID = 19118433.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


78. Wu XJ, Wang JP, Wang L, He XS, Zou YF, Lian L, Zhang LJ, Lan P: Increased rate change over time of a sphincter-saving procedure for lower rectal cancer. Chin Med J (Engl); 2008 Apr 5;121(7):636-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased rate change over time of a sphincter-saving procedure for lower rectal cancer.
  • BACKGROUND: Total mesorectal excision (TME) has increased the rate of sphincter-preservation (SP) for more patients with low-lying rectal cancer.
  • Here, we analyze the change of sphincter preserving rates in lower rectal cancer and their related factors.
  • Significant differences were detected between the two time periods in gender, blood transfusion volume and Dukes' stage (P < 0.05).
  • [MeSH-minor] Adult. Aged. Anal Canal / surgery. Anastomosis, Surgical. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466685.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


79. Grimm M, Lazariotou M, Kircher S, Höfelmayr A, Germer CT, von Rahden BH, Waaga-Gasser AM, Gasser M: Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer--indications for anti-TNF-α agents in cancer treatment. Anal Cell Pathol (Amst); 2010;33(3):151-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer--indications for anti-TNF-α agents in cancer treatment.
  • METHODS: Expression of Tumor necrosis factor-alpha (TNF-α) was analyzed in colorectal cancer specimen and the cancer cell line HT-29 by immunohistochemistry and RT-PCR.
  • High TNF-α expression was significantly associated with positive lymph node stage and recurrence of the tumor.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Oncol (Dordr). 2011 Aug;34(4):407-9
  • (PMID = 20978325.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC4605536
  •  go-up   go-down


80. Kayes OJ, Loddo M, Patel N, Patel P, Minhas S, Ambler G, Freeman A, Wollenschlaeger A, Ralph DJ, Stoeber K, Williams GH: DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma. Clin Cancer Res; 2009 Dec 01;15(23):7335-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma.
  • We have analyzed replication licensing factors (RLF), together with DNA ploidy status, to investigate their role in progression of penile squamous cell carcinoma and to assess their utility as novel prognostic tools.
  • Accelerated cell cycle progression was linked to increasing tumor size, stage, and depth of invasion.
  • Aneuploid tumors significantly correlated with tumor grade (P < 0.0001).
  • Our results also identify the DNA replication initiation pathway as a potentially attractive therapeutic target in penile squamous cell carcinoma.
  • [MeSH-major] Aneuploidy. Carcinoma / genetics. Carcinoma / therapy. Gene Expression Regulation, Neoplastic. Penile Neoplasms / genetics. Penile Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Cycle. Cell Cycle Proteins / biosynthesis. Cohort Studies. Geminin. Gene Expression Profiling. Humans. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Minichromosome Maintenance Complex Component 2. Nuclear Proteins / biosynthesis. Ploidies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):959-70 [19240714.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1295-300 [16278669.001]
  • [Cites] IARC Sci Publ. 1992;(120):45-173 [1284606.001]
  • [Cites] J Urol. 1993 Mar;149(3):492-7 [8437253.001]
  • [Cites] Nat Chem Biol. 2008 Jun;4(6):331-2 [18488006.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1128-34 [19293805.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1071-9 [12122098.001]
  • [Cites] J Urol. 2006 May;175(5):1700-4; discussion 1704-5 [16600735.001]
  • [Cites] Acta Neuropathol. 2007 Feb;113(2):119-27 [17160531.001]
  • [Cites] BJU Int. 2006 Sep;98(3):526-31 [16925747.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2712-8 [11555583.001]
  • [Cites] Br J Urol. 1993 Dec;72(6):941-5 [8306161.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):755-61 [9630184.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2417-25 [19318489.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):735-41 [16915294.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):1-8 [15183542.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):262-9 [15199392.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):247-56 [1574815.001]
  • [Cites] Exp Cell Res. 2005 Sep 10;309(1):56-67 [16005865.001]
  • [Cites] EMBO J. 1998 Dec 15;17(24):7219-29 [9857179.001]
  • [Cites] J Pathol. 2005 Feb;205(3):318-28 [15682442.001]
  • [Cites] J Cell Sci. 2004 Nov 15;117(Pt 24):5875-86 [15522891.001]
  • [Cites] Trends Cell Biol. 2002 Feb;12(2):72-8 [11849970.001]
  • [Cites] J Urol. 2005 Mar;173(3):816-9 [15711276.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6153-61 [17947481.001]
  • [Cites] Curr Opin Cell Biol. 2007 Dec;19(6):672-9 [18032010.001]
  • [Cites] J Urol. 2006 Jun;175(6):2103-8; discussion 2108 [16697813.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7 [9843993.001]
  • [Cites] Exp Cell Res. 2007 Oct 15;313(17):3789-99 [17689530.001]
  • [Cites] Br J Urol. 1993 Nov;72(5 Pt 2):817-9 [8281416.001]
  • [Cites] Anal Cell Pathol. 1998;17(4):189-200 [10391371.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):714-9 [15266314.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):799-806 [18756287.001]
  • [Cites] Gut. 2002 Mar;50(3):373-7 [11839717.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):476-86 [15928711.001]
  • [Cites] Annu Rev Biochem. 2002;71:333-74 [12045100.001]
  • [Cites] J Surg Oncol. 2008 May 1;97(6):487-95 [18425779.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):267-73 [12107111.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1384-93 [17406359.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4306-13 [14645419.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2510-7 [15814627.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):217-26 [12612656.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1524-5 [10551502.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1048-54 [12966424.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2855-64 [18843031.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Aug;29(4):185-98 [17879626.001]
  • [Cites] Ann Surg. 1921 Feb;73(2):141-60 [17864409.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1548-54 [18414413.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2027-41 [11493639.001]
  • (PMID = 19920109.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6263
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  • [Other-IDs] NLM/ PMC2788529; NLM/ UKMS27727
  •  go-up   go-down


81. Elser JJ, Kyle MM, Smith MS, Nagy JD: Biological stoichiometry in human cancer. PLoS One; 2007 Oct 10;2(10):e1028
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological stoichiometry in human cancer.
  • CONCLUSIONS/SIGNIFICANCE: Data for lung and colon tumors provide support for the GRH in human cancer.
  • The two-fold amplification of P content in colon and lung tumors may set the stage for potential P-limitation of their proliferation, as such differences often do for rapidly growing biota in ecosystems.
  • To account for these conflicting observations, we suggest that local environments in some organs select for neoplastic cells bearing mutations increasing cell division rate ("r-selected," as in colon and lung) while conditions elsewhere may select for reduced mortality rate ("K-selected," as in liver and kidney).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • Hazardous Substances Data Bank. Nitrogen, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2002 Sep 23;162(17):1985-93 [12230422.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5806-14 [11486020.001]
  • [Cites] Genes Dev. 2003 Jul 15;17(14):1709-13 [12865297.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2935-9 [8385351.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):699-703 [9872321.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11923-7 [16091465.001]
  • [Cites] Nat Clin Pract Nephrol. 2006 Mar;2(3):136-48 [16932412.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):924-35 [17109012.001]
  • [Cites] Annu Rev Med. 2007;58:239-52 [17100552.001]
  • [Cites] Colloids Surf B Biointerfaces. 2007 Mar 15;55(1):10-8 [17188467.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):213-21 [17301845.001]
  • [Cites] Curr Opin Genet Dev. 2007 Apr;17(2):157-62 [17324569.001]
  • [Cites] Annu Rev Genet. 1999;33:29-55 [10690403.001]
  • [Cites] Bone. 2000 Sep;27(3):333-8 [10962341.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4311-4 [11389050.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):733-41 [12428794.001]
  • (PMID = 17925876.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM060792; United States / NIGMS NIH HHS / GM / GM060792
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Ribosomal; 27YLU75U4W / Phosphorus; 63231-63-0 / RNA; 9007-49-2 / DNA; N762921K75 / Nitrogen
  • [Other-IDs] NLM/ PMC2000353
  •  go-up   go-down


82. Staudacher C, Di Palo S, Tamburini AM, Vignali A, Orsenigo E: [The role of neoadjuvant radio-chemotherapy in the treatment of rectal cancer]. Ann Ital Chir; 2007 Nov-Dec;78(6):493-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of neoadjuvant radio-chemotherapy in the treatment of rectal cancer].
  • [Transliterated title] Il ruolo della radiochemioterapia neoadiuvante nel trattamento del tumore del retto.
  • OBJECTIVE: To evaluate oncological and surgical outcome of patients submitted to neoadjuvant therapy for advanced rectal cancer.
  • PATIENTS AND METHOD: One hundred thirty eight patients (86 male, 52 female, mean age 61.4 years), with tumour of lower (58; 42%), middle (66; 48%), upper rectum (14; 10%), showing a clinical stage II (23; 17%) or III (115; 83%) and with an average distance from anal verge of 6.5 cm, submitted to fractionated "long-course" RT with CT locally staged by US and MR before and after neoadjuvant therapy and operated on after 4-6 weeks by its end.
  • Pre-treatment clinical stage was not significant.
  • Non-responder patients had worse prognosis (5-years survival 30%).

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510028.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


83. Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, Jani AB, Kindler HL, Mundt AJ, Roeske JC, Chmura SJ: Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys; 2008 Apr 1;70(5):1431-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
  • PURPOSE: To test the hypothesis that the volume of pelvic bone marrow (PBM) receiving 10 and 20 Gy or more (PBM-V(10) and PBM-V(20)) is associated with acute hematologic toxicity (HT) in anal cancer patients treated with concurrent chemoradiotherapy.
  • METHODS AND MATERIALS: We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy.
  • Endpoints included the white blood cell count (WBC), absolute neutrophil count (ANC), hemoglobin, and platelet count nadirs.
  • RESULTS: Twenty patients (42%) had Stage T3-4 disease; 15 patients (31%) were node positive.
  • Overall, 27 (56%), 24 (50%), 4 (8%), and 13 (27%) experienced acute Grade 3-4 leukopenia, neutropenia, anemia, and thrombocytopenia, respectively.
  • CONCLUSION: This analysis supports the hypothesis that increased low-dose radiation to PBM is associated with acute HT during chemoradiotherapy for anal cancer.
  • Techniques to limit bone marrow irradiation may reduce HT in anal cancer patients.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Bone Marrow / radiation effects

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17996390.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


84. Morris E, Quirke P, Thomas JD, Fairley L, Cottier B, Forman D: Unacceptable variation in abdominoperineal excision rates for rectal cancer: time to intervene? Gut; 2008 Dec;57(12):1690-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unacceptable variation in abdominoperineal excision rates for rectal cancer: time to intervene?
  • OBJECTIVE: To determine the variation in the rates of use of abdominoperineal excision (APE) by cancer network, hospital trust and surgeon across England between 1998 and 2004 and determine if any variation could be explained by differences in patient characteristics such as stage of disease, age, gender or socioeconomic deprivation.
  • DESIGN: Retrospective study of a population-based dataset comprised of cancer registry and hospital episode statistics data.
  • SETTING: All NHS providers of rectal cancer surgery within England.
  • PATIENTS: 31,223 patients diagnosed with rectal cancer and receiving a major abdominal procedure within the NHS in England between 1998 and 2004.
  • MAIN OUTCOME MEASURE: Rates and odds of use of APE were determined in relation to patient case-mix and each patient's managing surgeon, trust and cancer network.
  • Males, the economically deprived and those managed by surgeons operating on fewer than seven rectal cancer cases per year were all significantly more likely to receive an APE.
  • Reducing this variation will remove inequalities, reduce colostomy rates, and improve outcomes in rectal cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gut. 2009 Jan;58(1):146; author response 146-7 [19091835.001]
  • [CommentIn] Gut. 2009 Jan;58(1):150; author reply 150-2 [19091841.001]
  • [CommentIn] Gut. 2009 Jan;58(1):147; author reply 147-8 [19091837.001]
  • [CommentIn] Gut. 2009 Apr;58(4):608-9; author reply 609-10 [19299392.001]
  • [CommentIn] Gut. 2009 Feb;58(2):311; author reply 311-2 [19136525.001]
  • [CommentIn] Gut. 2010 Jan;59(1):139-40 [20007965.001]
  • [CommentIn] Gut. 2008 Dec;57(12):1643-5 [19022921.001]
  • (PMID = 18535029.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 9805
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


85. Hartshorn C, Eckert JJ, Hartung O, Wangh LJ: Single-cell duplex RT-LATE-PCR reveals Oct4 and Xist RNA gradients in 8-cell embryos. BMC Biotechnol; 2007;7:87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-cell duplex RT-LATE-PCR reveals Oct4 and Xist RNA gradients in 8-cell embryos.
  • BACKGROUND: The formation of two distinctive cell lineages in preimplantation mouse embryos is characterized by differential gene expression.
  • The cells of the inner cell mass are pluripotent and express high levels of Oct4 mRNA, which is down-regulated in the surrounding trophectoderm.
  • We, thus, postulated that simultaneous quantification of Oct4 and Xist transcripts in individual blastomeres at the 8-cell stage could be informative as to their subsequent fate.
  • We then undertook analysis of sets of blastomeres isolated from embryos at the 8-cell stage.
  • At this stage, all cells in the embryo are still pluripotent and morphologically equivalent.
  • Analysis of multiple embryos also shows that Xist and Oct4 expression levels are not correlated at the 8-cell stage, although transcription of both genes is up-regulated at this time in development.
  • With this technique, copy numbers of different RNAs can be accurately measured independently from their relative abundance in a cell, a goal that cannot be achieved using symmetric PCR.
  • The technique illustrated in this work is relevant to a wide array of applications, such as stem cell and cancer cell analysis and preimplantation genetic diagnostics.
  • [MeSH-major] Blastocyst Inner Cell Mass / metabolism. Gene Expression Profiling / methods. Gene Expression Regulation, Developmental / physiology. Octamer Transcription Factor-3 / metabolism. RNA, Untranslated / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 Apr;24(4):372-6 [10742100.001]
  • [Cites] Nat Protoc. 2007;2(10):2429-38 [17947984.001]
  • [Cites] Mol Hum Reprod. 2001 Feb;7(2):155-61 [11160841.001]
  • [Cites] Development. 2001 Apr;128(8):1275-86 [11262229.001]
  • [Cites] Cell Struct Funct. 2001 Jun;26(3):123-9 [11565804.001]
  • [Cites] Mol Reprod Dev. 2002 Apr;61(4):425-36 [11891913.001]
  • [Cites] Science. 2002 Apr 19;296(5567):557-9 [11964485.001]
  • [Cites] Genes Dev. 2002 May 15;16(10):1209-19 [12023300.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):14-5 [12097880.001]
  • [Cites] Nature. 2002 Jul 18;418(6895):293-300 [12124616.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1329-37 [12142391.001]
  • [Cites] Mol Reprod Dev. 2003 Jan;64(1):41-51 [12420298.001]
  • [Cites] Reprod Biomed Online. 2003 Mar;6(2):215-20 [12676002.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):857-62 [14661031.001]
  • [Cites] Science. 2004 Jan 30;303(5658):644-9 [14671313.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1933-8 [14769930.001]
  • [Cites] Nat Rev Microbiol. 2003 Nov;1(2):158-64 [15035045.001]
  • [Cites] Semin Cell Dev Biol. 2004 Oct;15(5):583-97 [15271304.001]
  • [Cites] J Biomol Tech. 2004 Sep;15(3):155-66 [15331581.001]
  • [Cites] Dev Biol. 1987 Feb;119(2):520-31 [3803716.001]
  • [Cites] Trends Genet. 1991 Oct;7(10):323-9 [1781030.001]
  • [Cites] Mol Reprod Dev. 1993 Jun;35(2):121-6 [8318217.001]
  • [Cites] Dev Biol. 1994 Nov;166(1):259-67 [7958450.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1995 Nov 29;350(1333):253-60 discussion 260-1 [8570689.001]
  • [Cites] Hum Reprod. 1995 Oct;10(10):2787-92 [8567814.001]
  • [Cites] Genes Dev. 1997 May 15;11(10):1207-25 [9171367.001]
  • [Cites] Cell. 1997 Sep 5;90(5):907-16 [9298902.001]
  • [Cites] Cell. 1997 Oct 3;91(1):99-107 [9335338.001]
  • [Cites] Mol Hum Reprod. 1998 Nov;4(11):1021-31 [9835353.001]
  • [Cites] Reprod Biomed Online. 2004 Dec;9(6):623-9 [15670408.001]
  • [Cites] Stem Cells. 2005 Feb;23(2):146-9 [15671139.001]
  • [Cites] BMC Biotechnol. 2005;5:2 [15649321.001]
  • [Cites] J Biol Chem. 2005 Feb 25;280(8):6265-8 [15640145.001]
  • [Cites] Mol Hum Reprod. 2005 Mar;11(3):173-81 [15695770.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(12):5084-94 [15923625.001]
  • [Cites] Reprod Biomed Online. 2005 May;10(5):607-16 [15949218.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8609-14 [15937116.001]
  • [Cites] Mol Reprod Dev. 2005 Oct;72(2):182-90 [15973686.001]
  • [Cites] Reprod Biomed Online. 2005 Aug;11(2):206-18 [16168219.001]
  • [Cites] Fertil Steril. 2005 Nov;84(5):1547-50 [16275269.001]
  • [Cites] Dev Biol. 2005 Dec 1;288(1):234-47 [16271712.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Dec;6(12):919-28 [16341078.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2322-8 [16258706.001]
  • [Cites] Nature. 2006 Jan 12;439(7073):216-9 [16227970.001]
  • [Cites] Anal Biochem. 2006 Jun 1;353(1):124-32 [16540077.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] Mol Hum Reprod. 2000 Aug;6(8):707-11 [10908280.001]
  • (PMID = 18067662.001).
  • [ISSN] 1472-6750
  • [Journal-full-title] BMC biotechnology
  • [ISO-abbreviation] BMC Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Octamer Transcription Factor-3; 0 / Pou5f1 protein, mouse; 0 / RNA, Long Noncoding; 0 / RNA, Untranslated; 0 / XIST non-coding RNA; 63231-63-0 / RNA
  • [Other-IDs] NLM/ PMC2246118
  •  go-up   go-down


86. Jia SQ, Niu ZJ, Zhang LH, Zhong XY, Shi T, Du H, Zhang GG, Hu Y, Su XL, Ji JF: Identification of prognosis-related proteins in advanced gastric cancer by mass spectrometry-based comparative proteomics. J Cancer Res Clin Oncol; 2009 Mar;135(3):403-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of prognosis-related proteins in advanced gastric cancer by mass spectrometry-based comparative proteomics.
  • PURPOSE: The objective of this study was to identify differentially expressed proteins of advanced gastric cancer from patients with different prognosis using NanoLC-MS/MS (LTQ) (nanoflow liquid chromatography system interfaced with a linear ion trap LTQ mass spectrometer).
  • METHODS: Eight gastric cancer patients with relatively early TNM stage and survival time >34 months were identified as good survival (group G), while the other eight with late stage and survival time <15 months as poor survival (group P).
  • Database searches were done against NCBI non-redundant database and SWISS-PROT database and the identified proteins were classified through an online Web Gene Ontology Annotation Plot tool.
  • Among those, the down-regulated expression of S100P was verified to claim a poor clinical outcome of gastric cancer patients (P = 0.0375).
  • CONCLUSION: The MS-based proteomics approach is efficient in identifying differentially expressed proteins in relation to prognosis of advanced gastric cancer patients.
  • These differentially expressed proteins could be potential prognosis-related cancer markers and deserve further validation and functional study.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2006 Jan 7;12(1):17-20 [16440411.001]
  • [Cites] Proteomics. 2005 Mar;5(4):1160-6 [15759317.001]
  • [Cites] Oncol Rep. 2007 May;17(5):1101-7 [17390051.001]
  • [Cites] Oncogene. 2004 Dec 2;23(56):9042-51 [15489895.001]
  • [Cites] Cancer Sci. 2005 Nov;96(11):738-46 [16271067.001]
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:5-11 [12772880.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1339-45 [11396210.001]
  • [Cites] Am J Pathol. 2005 Jan;166(1):81-92 [15632002.001]
  • [Cites] Gastric Cancer. 2004;7(2):61-77 [15224192.001]
  • [Cites] Int J Oncol. 2000 Feb;16(2):231-40 [10639564.001]
  • [Cites] Histol Histopathol. 2000 Apr;15(2):455-62 [10809364.001]
  • [Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W293-7 [16845012.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2621-7 [17570016.001]
  • [Cites] J Chromatogr A. 2005 Mar 4;1067(1-2):73-83 [15844511.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1199-207 [16424059.001]
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2007 Sep;10 (5):454-7 [17851788.001]
  • [Cites] Gastric Cancer. 2004;7(3):160-6 [15449204.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):91-8 [16450401.001]
  • [Cites] Biochim Biophys Acta. 2006 Oct;1764(10):1607-17 [17030026.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):395-402 [17067748.001]
  • [Cites] J Proteome Res. 2007 Feb;6(2):801-8 [17269736.001]
  • [Cites] J Pathol. 2003 May;200(1):39-46 [12692839.001]
  • [Cites] Chin Med J (Engl). 1988 Jul;101(7):488-9 [3147845.001]
  • [Cites] Br J Surg. 1992 Apr;79(4):293-9 [1576492.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5243-50 [16097765.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1651-64 [9448610.001]
  • [Cites] J Pathol. 2003 Sep;201(1):63-74 [12950018.001]
  • [Cites] Verh Dtsch Ges Pathol. 2003;87:123-9 [16888903.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5356-64 [16061848.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 8;238(1):66-70 [9299453.001]
  • [Cites] Genomics. 1995 Feb 10;25(3):638-43 [7759097.001]
  • [Cites] FASEB J. 2005 Feb;19(2):243-5 [15548588.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1287-93 [15138568.001]
  • [Cites] J Surg Oncol. 2007 Mar 15;95(4):324-31 [17066404.001]
  • [Cites] Mol Cell Proteomics. 2007 Sep;6(9):1459-72 [17569891.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2179-83 [15259061.001]
  • [Cites] Anticancer Res. 1997 Sep-Oct;17(5A):3393-401 [9413178.001]
  • (PMID = 18830628.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proteins
  •  go-up   go-down


87. Scott H, Khoury J, Moore BA, Weissman S: Routine anal cytology screening for anal squamous intraepithelial lesions in an urban HIV clinic. Sex Transm Dis; 2008 Feb;35(2):197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine anal cytology screening for anal squamous intraepithelial lesions in an urban HIV clinic.
  • OBJECTIVES: The purpose of this study is to describe our experience with routine anal cancer screening using anal cytology, determine risk factors for abnormal anal cytology, and determine if an association exists between cytology and histology in patients with HIV infection.
  • METHODS: Demographics, CD4+ T-cell count, STD history, and cytology and histology data were extracted from medical charts of patients seen between November 1, 2002, and November 30, 2004.
  • Multivariate analysis was conducted using logistic regression controlling for age, race, sex, CD4+ T-cell nadir, and HIV exposure category.
  • RESULTS: Overall, 276 of 560 of the clinic patients received a screening anal cytology during the study period.
  • Of these patients, 11 were excluded from the analysis and 74 of 265 (27.9%) patients screened had an abnormal anal cytology.
  • They were also more likely to have a lower CD4+ nadir (142 cells/mm3 vs. 223 cells/mm3, P = 0.005) and CD4+ at time of anal cytology (353 cells/mm3 vs. 497 cells/mm3, P <0.001).
  • Those with an abnormal anal cytology also had higher occurrence of anal disease on perianal visual inspection (30% vs. 9%, P <0.001) and were more likely to have a history of genital warts (23% vs. 12%, P = 0.02) or herpes (35% vs. 22%, P = 0.02).
  • Two patients had anal intraepithelial neoplasia (AIN) I, 2 AIN II, 3 AIN III, and 2 squamous cell carcinoma in situ on histology.
  • CONCLUSION: Routine anal cytology screening is a feasible tool to incorporate into HIV care for patients regardless of gender and HIV risk factors.
  • [MeSH-major] Anus Neoplasms / diagnosis. HIV Infections / complications. Neoplasms, Squamous Cell / pathology. Urban Health Services / organization & administration
  • [MeSH-minor] Adult. Aged. Anal Canal / pathology. Colonoscopy / methods. Female. Follow-Up Studies. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis


88. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, Yokoe H, Tanzawa H: Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer; 2006 Mar 13;94(5):717-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis.
  • Our previous study using proteomic profiling showed that significant upregulation of stathmin occurs in oral squamous-cell carcinoma (OSCC)-derived cell lines.
  • In the current study, to determine the potential involvement of stathmin in OSCC, we evaluated the state of stathmin protein and mRNA expression in OSCC-derived cell lines and human primary OSCCs.
  • A significant increase in stathmin expression was observed in all OSCC-derived cell lines examined compared to human normal oral keratinocytes.
  • Moreover, stathmin expression status was correlated with the TNM stage grading.
  • These results suggest that expression of stathmin could contribute to cancer progression/prognosis, and that stathmin may have potential as a biomarker and a therapeutic target for OSCC.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Mouth Neoplasms / genetics. Stathmin / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1993 Oct;8(10):2869-72 [8397372.001]
  • [Cites] J Biol Chem. 1991 Nov 5;266(31):21004-10 [1939149.001]
  • [Cites] Prostate. 1995 Aug;27(2):102-9 [7638082.001]
  • [Cites] Cell. 1996 Feb 23;84(4):623-31 [8598048.001]
  • [Cites] Biotechnol Genet Eng Rev. 1996;13:19-50 [8948108.001]
  • [Cites] Cell Signal. 1997 May-Jun;9(3-4):249-55 [9218124.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):701-9 [9743287.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):346-56 [15637397.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1915-21 [15870709.001]
  • [Cites] Int J Oncol. 2005 Jul;27(1):59-67 [15942644.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):269-73 [16012760.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):704-13 [16094606.001]
  • [Cites] Mol Carcinog. 2000 Mar;27(3):158-65 [10708477.001]
  • [Cites] FEBS Lett. 2000 Mar 10;469(2-3):155-8 [10713262.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1202-9 [10786892.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):837-46 [10866210.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3537-41 [10910066.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):311-8 [10917544.001]
  • [Cites] Anal Biochem. 2000 Aug 15;284(1):49-59 [10933855.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3949-56 [11051243.001]
  • [Cites] Cancer Invest. 2000;18(8):722-30 [11107442.001]
  • [Cites] Curr Opin Mol Ther. 2000 Dec;2(6):633-42 [11249740.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1494-9 [11301397.001]
  • [Cites] Mt Sinai J Med. 2002 Oct;69(5):299-304 [12415323.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6598-605 [12438255.001]
  • [Cites] J Dent Res. 2003 Aug;82(8):607-11 [12885844.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):225-31 [15069686.001]
  • [Cites] J Cell Biochem. 2004 Oct 1;93(2):242-50 [15368352.001]
  • [Cites] J Biol Chem. 1983 Sep 10;258(17):10786-93 [6577004.001]
  • [Cites] J Biol Chem. 1988 Sep 15;263(26):12813-5 [3417633.001]
  • [Cites] Leukemia. 1993 Oct;7(10):1538-46 [8412315.001]
  • (PMID = 16495930.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / STMN1 protein, human; 0 / Stathmin
  • [Other-IDs] NLM/ PMC2361217
  •  go-up   go-down


89. Yamashita S, Ikeda M, Kim HM, Hirose H, Kagawa Y, Takemasa I, Mizushima T, Ishii H, Yamamoto H, Sekimoto M, Doki Y, Mori M: [A case of lateral lymph node metastasis of submucosal rectal cancer]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2629-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of lateral lymph node metastasis of submucosal rectal cancer].
  • We report a case of lateral lymph node metastasis of submucosal rectal cancer.
  • Screening colonoscopy revealed an 18 mm 0-Is rectal cancer in Rb 6 cm from anal verge.
  • Laparoscopic low anterior resection was then performed and no metastasis of lymph nodes (pSM, N0/stage I) was found.


90. Cai W, Chen K, He L, Cao Q, Koong A, Chen X: Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging; 2007 Jun;34(6):850-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Cetuximab, a chimeric monoclonal antibody targeting epidermal growth factor receptor (EGFR) on the surface of cancer cells, was approved by the FDA to treat patients with metastatic colorectal cancer.
  • It is currently also in advanced-stage development for the treatment of several other solid tumors.
  • Human dosimetry estimation indicated that the tracer may be safely administered to human patients for tumor diagnosis, with the dose-limiting organ being the liver.
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Cell Line, Tumor. Cetuximab. Humans. Mice. Neoplasm Transplantation. Radiometry

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1510-1 [17447062.001]
  • [Cites] J Nucl Med. 1995 Dec;36(12 ):2363-71 [8523133.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] J Nucl Med. 2005 Nov;46(11):1881-8 [16269603.001]
  • [Cites] Nano Lett. 2006 Apr;6(4):669-76 [16608262.001]
  • [Cites] J Nucl Med. 2005 Nov;46(11):1898-906 [16269605.001]
  • [Cites] J Nucl Med. 2006 Jan;47(1):130-9 [16391197.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):32-43 [15688065.001]
  • [Cites] J Nucl Med. 2006 Jan;47(1):113-21 [16391195.001]
  • [Cites] J Nucl Med. 2003 Oct;44(10 ):1663-70 [14530484.001]
  • [Cites] J Immunol Methods. 1984 Aug 3;72(1):77-89 [6086763.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9673-81 [17018625.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:18S-27S [15653648.001]
  • [Cites] J Nucl Med. 2006 Jul;47(7):1172-80 [16818952.001]
  • [Cites] J Control Release. 2000 Mar 1;65(1-2):271-84 [10699287.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2787-99 [12860957.001]
  • [Cites] J Nucl Med. 2007 Feb;48(2):304-10 [17268029.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2610-6 [15226328.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23 (9):1137-46 [16151407.001]
  • [Cites] Semin Oncol. 2003 Jun;30(3 Suppl 7):3-14 [12840796.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8786-93 [16246975.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2624-33 [17121909.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10 ):1707-18 [16204722.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 4;88(23):1770-6 [8944008.001]
  • [Cites] Eur J Nucl Med. 2001 Sep;28(9):1326-35 [24578054.001]
  • [Cites] J Nucl Med. 2006 Dec;47(12 ):2048-56 [17138749.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1126-36 [16151406.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):271-9 [15799827.001]
  • [Cites] Ann Pharmacother. 2006 Feb;40(2):241-50 [16403849.001]
  • [Cites] Anal Biochem. 1984 Oct;142(1):68-78 [6440451.001]
  • [Cites] Curr Opin Oncol. 2004 Jul;16(4):385-90 [15187895.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10 ):1818-24 [7562049.001]
  • [Cites] J Nucl Med. 1998 Nov;39(11):1944-51 [9829587.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Nucl Med. 2004 Aug;45(8):1390-7 [15299066.001]
  • [Cites] J Nucl Med. 2004 Oct;45(10 ):1683-7 [15471833.001]
  • (PMID = 17262214.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA114747; United States / NCI NIH HHS / CA / R21 CA102123; United States / NIBIB NIH HHS / EB / R21 EB001785; United States / NCI NIH HHS / CA / R24 CA93862; United States / NCI NIH HHS / CA / U54 CA119367
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Copper Radioisotopes; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


91. Chan AK, Wong AO, Jenken DA: Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer--is it equivalent to 5-FU infusion plus leucovorin and radiotherapy? Int J Radiat Oncol Biol Phys; 2010 Apr;76(5):1413-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer--is it equivalent to 5-FU infusion plus leucovorin and radiotherapy?
  • PURPOSE: The aim of this retrospective case-matching study was to compare the treatment outcomes and acute toxicity of preoperative radiotherapy (RT) with capecitabine vs. preoperative RT with intermittent 5-fluorouracil (5-FU) infusion, leucovorin, and mitomycin C in rectal cancer.
  • METHODS AND MATERIALS: We matched 34 patients who were treated with preoperative concurrent capecitabine and 50 Gy of RT by their clinical T stage (T3 or T4) and the tumor location (<or=7 cm or >7 cm from the anal verge) with another 68 patients who were treated with preoperative intermittent 5-FU infusion, leucovorin, mitomycin C, and 50 Gy of RT for a comparison of the pathologic tumor response, local control, distant failure, and survival rates.
  • The acute toxicity profile was comparable, with little Grade 3 and 4 toxicity.
  • CONCLUSIONS: When administered with concurrent preoperative RT, both capecitabine and intermittent 5-FU infusion with leucovorin modulation provided comparable pathologic tumor response, local control, relapse-free survival, and disease-specific survival rates in rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20338475.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


92. Hegele A, Hofmann R, Kosche B, Kropf J: Evaluation of cellular fibronectin plasma levels as a useful staging tool in different stages of transitional cell carcinoma of the bladder and renal cell carcinoma. Biomark Insights; 2007 Feb 07;2:1-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of cellular fibronectin plasma levels as a useful staging tool in different stages of transitional cell carcinoma of the bladder and renal cell carcinoma.
  • Reliable markers for both renal cell carcinoma (RCC) and transitional cell carcinoma of the bladder (TCC) are lacking.During tumor progression and invasion components of extracellular matrix (ECM) are degraded and parts of these different components are detectable in plasma.
  • Sixty patients with non-malignant urological disorders were recruited as control group.
  • In patients with muscle invasive TCC significant higher cFN levels (p < 0.05) could be demonstrated compared to non-muscle invasive TCC.
  • Similar results were found in RCC with significant elevated cFN levels in metastatic RCC (p < 0.005) compared to localized stage of disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biomarkers. 2005 Jul-Aug;10(4):258-94 [16191485.001]
  • [Cites] J Urol. 2005 Nov;174(5):1771-5; discussion 1775-6 [16217281.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):30-5 [15912517.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):678-86 [16129368.001]
  • [Cites] Br J Cancer. 1997;76(6):777-83 [9310245.001]
  • [Cites] Eur Urol. 1997;31(1):40-8 [9032533.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):364-71 [8903479.001]
  • [Cites] Exp Cell Res. 1995 Nov;221(1):83-91 [7589259.001]
  • [Cites] Cancer Metastasis Rev. 1995 Sep;14(3):173-89 [8548867.001]
  • [Cites] J Hepatol. 1995;22(2 Suppl):77-81 [7665854.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):578-82 [7880741.001]
  • [Cites] Clin Chem. 1995 Sep;41(9):1283-7 [7656438.001]
  • [Cites] J Urol. 1993 Feb;149(2):268-71 [8426398.001]
  • [Cites] Jpn J Cancer Res. 1992 Dec;83(12):1327-33 [1483947.001]
  • [Cites] Urol Clin North Am. 1992 Aug;19(3):429-33 [1636228.001]
  • [Cites] Anal Biochem. 1991 Aug 15;197(1):258-65 [1952074.001]
  • [Cites] J Cell Biol. 1986 Nov;103(5):1671-7 [3023390.001]
  • [Cites] Arch Dermatol. 1988 Feb;124(2):221-5 [3341802.001]
  • [Cites] J Cell Biol. 1982 Nov;95(2 Pt 1):369-77 [6128348.001]
  • [Cites] Tumour Biol. 2004 May-Jun;25(3):111-6 [15361707.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1496-500 [15371878.001]
  • [Cites] Urol Res. 2003 Feb;30(6):363-6 [12599015.001]
  • [Cites] Mod Pathol. 2002 Aug;15(8):826-30 [12181267.001]
  • [Cites] Urol Res. 2002 May;30(2):126-9 [12086018.001]
  • [Cites] Eur Urol. 2001 Mar;39(3):292-9 [11275722.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):889-94 [11948468.001]
  • [Cites] Thromb Res. 2002 Jan 1;105(1):37-41 [11864705.001]
  • [Cites] J Urol. 2002 Jan;167(1):80-3 [11743280.001]
  • [Cites] Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78 [11514784.001]
  • [Cites] J Urol. 2001 Aug;166(2):470-5 [11458049.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3585-94 [10999749.001]
  • [Cites] Urol Int. 2000;64(4):198-201 [10895085.001]
  • [Cites] Cancer Lett. 2000 Jul 31;155(2):199-205 [10822136.001]
  • [Cites] J Urol. 2000 Feb;163(2):408-17 [10647643.001]
  • [Cites] Clin Chim Acta. 2006 Oct;372(1-2):83-93 [16730689.001]
  • [Cites] J Thromb Haemost. 2006 Jul;4(7):1461-9 [16839338.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1193-5 [16709950.001]
  • [Cites] Curr Pharm Des. 2005;11(7):881-91 [15777241.001]
  • (PMID = 19662188.001).
  • [Journal-full-title] Biomarker insights
  • [ISO-abbreviation] Biomark Insights
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2717843
  • [Keywords] NOTNLM ; Biological markers / Extracellular matrix / Invasion / TRFIA / tumor progression
  •  go-up   go-down


93. Pedretti M, Verpelli C, Mårlind J, Bertani G, Sala C, Neri D, Bello L: Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer; 2010 Sep 7;103(6):827-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the therapeutic properties of temozolomide in combination with F16-IL2, a clinical-stage immunocytokine consisting of human interleukin (IL)-2 fused to the human antibody F16, specific to the A1 domain of tenascin-C.
  • CONCLUSION: The combined use of temozolomide with F16-IL2 deserves clinical investigations, which will be facilitated by the excellent safety profile in cynomolgus monkeys, and by the fact that F16-IL2 is in clinical trials in patients with cancer.
  • [MeSH-minor] Animals. Apoptosis. Cell Proliferation. Humans. Immunohistochemistry. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Tissue Distribution

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucl Med Biol. 2007 Oct;34(7):779-85 [17921029.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4940-8 [17510424.001]
  • [Cites] Biochim Biophys Acta. 2007 Dec;1776(2):175-92 [17920773.001]
  • [Cites] J Nucl Med. 2008 Jan;49(1):30-8 [18077533.001]
  • [Cites] FASEB J. 2008 Mar;22(3):659-61 [17942826.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6515-24 [18927291.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2275-83 [19005180.001]
  • [Cites] Lung Cancer. 2009 Apr;64(1):28-33 [18799229.001]
  • [Cites] Int J Cancer. 2010 Jul 1;127(1):101-10 [19877124.001]
  • [Cites] J Urol. 2010 Dec;184(6):2540-8 [21030045.001]
  • [Cites] Eur J Nucl Med. 2000 May;27(5):601-9 [10853818.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2585-97 [10914698.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] J Immunol. 2001 Sep 15;167(6):3129-38 [11544298.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1659-65 [11861281.001]
  • [Cites] Nat Biotechnol. 2002 Mar;20(3):264-9 [11875427.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] Int J Cancer. 2002 Nov 1;102(1):75-85 [12353237.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1695-700 [12414516.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):571-9 [12576420.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3202-10 [12810649.001]
  • [Cites] J Neuroimmunol. 2003 Jul;140(1-2):49-60 [12864971.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):133-46 [12957288.001]
  • [Cites] Trends Immunol. 2003 Nov;24(11):603-9 [14596885.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4384-92 [12933583.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):415-27 [14760060.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4527-37 [15240545.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Int J Cancer. 1994 Dec 1;59(5):612-8 [7525495.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] J Clin Lab Anal. 1996;10(3):160-6 [8731505.001]
  • [Cites] Cancer Treat Rev. 1997 Jan;23(1):35-61 [9189180.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1195-201 [9515805.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):21769-76 [9705314.001]
  • [Cites] Structure. 1999 Apr 15;7(4):381-90 [10196121.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):984-8 [10504699.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):241-5 [15655548.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Int J Cancer. 2005 Aug 20;116(2):304-13 [15800913.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):436-46 [15928674.001]
  • [Cites] Expert Opin Ther Targets. 2005 Jun;9(3):491-500 [15948669.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] Nat Rev Drug Discov. 2006 Feb;5(2):147-59 [16424916.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):343-57 [16622479.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3200-8 [16707621.001]
  • [Cites] Neurol Res. 2006 Jul;28(5):518-22 [16808882.001]
  • [Cites] J Nucl Med. 2006 Jul;47(7):1127-35 [16818947.001]
  • [Cites] Nucl Med Biol. 2006 Jul;33(5):661-6 [16843841.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4738-46 [16899625.001]
  • [Cites] J Nucl Med. 2006 Oct;47(10):1707-16 [17015908.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6217-23 [17947489.001]
  • (PMID = 20736949.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ PMC2966626
  •  go-up   go-down


94. Chen JJ, Yang BL, Zhang JX, Xu WP, Shao ZM, Wu J: The evaluation and optimization of intraoperative touch imprint cytology for sentinel lymph nodes in early-stage breast cancer in China. World J Surg; 2010 Oct;34(10):2325-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evaluation and optimization of intraoperative touch imprint cytology for sentinel lymph nodes in early-stage breast cancer in China.
  • BACKGROUND: Accurate intraoperative diagnosis of sentinel lymph node (SLN) metastasis reduces the need for additional surgery in patients with involved nodes.
  • The present study evaluates the clinical value of multiple cross-sectional touch imprint cytology (TIC) as an intraoperative assessment for the diagnosis of SLN metastasis.
  • Serial sectioning of the SLNs at 100-microm intervals with hematoxylin-eosin (H&E) staining was used as the gold standard for pathological diagnosis.
  • Limiting intraoperative TIC to the first three harvested SLNs in the diagnosis of SLN metastasis may make this diagnostic procedure significantly cheaper and easier for pathologists to perform.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Histocytological Preparation Techniques / methods. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2008 May;247(5):839-42 [18438122.001]
  • [Cites] J Surg Oncol. 2004 Feb;85(2):82-6; discussion 87 [14755508.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1140-7 [12429792.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):966-78 [10888772.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):296-303 [12607596.001]
  • [Cites] Eur J Surg Oncol. 2009 Sep;35(9):921-7 [19233602.001]
  • [Cites] J Surg Oncol. 2003 Oct;84(2):68-73 [14502779.001]
  • [Cites] Br J Surg. 1999 Oct;86(10):1346-8 [10540148.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):842-5 [12766591.001]
  • [Cites] Ann Surg. 2004 Jan;239(1):61-6 [14685101.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):333-9 [11986184.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1309-15 [18253802.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Aug;27(4):187-94 [16220829.001]
  • [Cites] Ann Surg Oncol. 2001 Aug;8(7):592-7 [11508621.001]
  • [Cites] ANZ J Surg. 2003 Aug;73(8):597-9 [12887528.001]
  • [Cites] Br J Surg. 2000 May;87(5):597-601 [10792316.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1068-80 [16106479.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(5):617-20 [16446084.001]
  • [Cites] World J Surg. 2002 Nov;26(11):1365-9 [12297929.001]
  • [Cites] Eur Radiol. 2008 Sep;18(9):1761-73 [18414872.001]
  • [Cites] Am Surg. 2003 May;69(5):419-23 [12769215.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1166-70 [14654472.001]
  • [Cites] Adv Anat Pathol. 2002 Jul;9(4):233-43 [12072814.001]
  • [Cites] N Engl J Med. 2003 Aug 7;349(6):546-53 [12904519.001]
  • [Cites] Am Surg. 2001 Jan;67(1):86-91 [11206905.001]
  • [Cites] Ann Surg Oncol. 1998 Dec;5(8):689-94 [9869514.001]
  • [Cites] Ann Surg Oncol. 2004 Aug;11(8):747-50 [15249334.001]
  • (PMID = 20567971.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Chiappa A, Biffi R, Zbar AP, Luca F, Crotti C, Bertani E, Biella F, Zampino G, Orecchia R, Fazio N, Venturino M, Crosta C, Pruneri GC, Grassi C, Andreoni B: Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003. Int J Colorectal Dis; 2005 May;20(3):221-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003.
  • BACKGROUND AND AIMS: This study reviewed the results of surgery for distal rectal cancer (where the tumour was within 6 cm of the anal verge) following the introduction of total mesorectal excision for rectal cancer in one institution.
  • PATIENTS AND METHODS: One hundred and fifty-three patients who had undergone elective curative surgical resection of rectal cancer within 6 cm of the anal verge were included.
  • On multivariate analysis type of surgery (P=0.025) and tumour stage (P=0.043), were associated with local recurrence, but only stage was a significant prognosticator of overall survival (P=0.0006).
  • CONCLUSION: With the practice of total mesorectal excision, APR was still necessary in 40% of patients with rectal cancer within 6 cm of the anal verge.
  • [MeSH-major] Carcinoma / surgery. Digestive System Surgical Procedures / methods. Postoperative Care / methods. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2002 Oct;26(10):1272-6 [12205546.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1031-3 [7648142.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):747-51 [9221846.001]
  • [Cites] Tech Coloproctol. 2001 Aug;5(2):97-102 [11862566.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Dis Colon Rectum. 1990 Feb;33(2):117-21 [2298097.001]
  • [Cites] Br J Surg. 1996 Mar;83(3):375-9 [8665198.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Br J Surg. 1985 Jan;72(1):34-7 [3967128.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1142-9 [12190680.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):473-83; discussion 483-6 [11330574.001]
  • [Cites] N Engl J Med. 1985 Jun 20;312(25):1604-8 [4000199.001]
  • [Cites] Dis Colon Rectum. 2001 Jul;44(7):947-54 [11496074.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):117 [9102254.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):799-802 [7543403.001]
  • [Cites] Dis Colon Rectum. 1991 Apr;34(4):317-22 [2007349.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):974-80 [12905551.001]
  • [Cites] Aust N Z J Surg. 2000 Oct;70(10 ):704-9 [11021483.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1501-5 [11683749.001]
  • [Cites] Br J Surg. 1999 Sep;86(9):1164-70 [10504371.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):751-7 [11087640.001]
  • [Cites] Eur J Surg. 1996 Aug;162(8):643-8 [8891623.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):659-63 [6478151.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1710-2 [11156455.001]
  • [Cites] Surgery. 1998 Oct;124(4):612-7; discussion 617-8 [9780979.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1408-16 [3345493.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):857-66 [12130870.001]
  • [Cites] Eur J Surg Oncol. 2003 Apr;29(3):239-43 [12657233.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):72-9 [12513964.001]
  • [Cites] Dis Colon Rectum. 1996 Mar;39(3):323-8 [8603556.001]
  • [Cites] Dis Colon Rectum. 1992 Mar;35(3):238-41 [1740068.001]
  • [Cites] Eur J Surg Oncol. 1995 Feb;21(1):11-5 [7851543.001]
  • [Cites] Eur J Surg Oncol. 1995 Dec;21(6):640-3 [8631412.001]
  • [Cites] Colorectal Dis. 2001 May;3(3):179-84 [12790986.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):895-903 [12130878.001]
  • [Cites] Ann Surg. 1990 Jun;211(6):745-51; discussion 751-2 [2357137.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):979-83 [9715152.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1261-6 [14515297.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):80-5 [12513965.001]
  • [Cites] Chir Ital. 2003 May-Jun;55(3):333-44 [12872567.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):379-84 [10201783.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):48-58 [14719151.001]
  • [Cites] Br J Surg. 1998 Apr;85(4):526-9 [9607540.001]
  • (PMID = 15602647.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Liang CH, Wang CC, Lin YC, Chen CH, Wong CH, Wu CY: Iron oxide/gold core/shell nanoparticles for ultrasensitive detection of carbohydrate-protein interactions. Anal Chem; 2009 Sep 15;81(18):7750-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in the expression of cell surface glycan are often associated with malignant metastasis.
  • A highly sensitive assay that is capable of detecting low levels of cancer-associated carbohydrate antigens can be a powerful tool for early diagnosis.
  • Well-defined recognition systems, namely, mannose derivatives (Man1, Man4, and Man9) with a mannose binding lectin (Concanavalin A) and a stage-specific embryonic antigens-3 (SSEA-3) with a monoclonal antibody (anti-SSEA-3) were chosen to establish this detection tool.

  • Hazardous Substances Data Bank. FERRIC OXIDE .
  • Hazardous Substances Data Bank. HEMATITE .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689135.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Carbohydrates; 0 / Ferric Compounds; 0 / Proteins; 11028-71-0 / Concanavalin A; 1K09F3G675 / ferric oxide; 7440-57-5 / Gold
  •  go-up   go-down


97. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, González-Neira A, Benítez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruening T, Haas S, Dörk T, Schürmann P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomäki K, von Smitten K, Blomqvist C, Mannermaa A, Uusitupa M, Eskelinen M, Tengström M, Kosma VM, Kataja V, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Australian Ovarian Cancer Management Group, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Devilee P, van Asperen CJ, Jacobi CE, Tollenaar RA, Huijts PE, Klijn JG, Chang-Claude J, Kropp S, Slanger T, Flesch-Janys D, Mutschelknauss E, Salazar R, Wang-Gohrke S, Couch F, Goode EL, Olson JE, Vachon C, Fredericksen ZS, Giles GG, Baglietto L, Severi G, Hopper JL, English DR, Southey MC, Haiman CA, Henderson BE, Kolonel LN, Le Marchand L, Stram DO, Hunter DJ, Hankinson SE, Cox DG, Tamimi R, Kraft P, Sherman ME, Chanock SJ, Lissowska J, Brinton LA, Peplonska B, Klijn JG, Hooning MJ, Meijers-Heijboer H, Collee JM, van den Ouweland A, Uitterlinden AG, Liu J, Lin LY, Yuqing L, Humphreys K, Czene K, Cox A, Balasubramanian SP, Cross SS, Reed MW, Blows F, Driver K, Dunning A, Tyrer J, Ponder BA, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gabrieau V, Sigurdson A, Doody M, Struewing JP, Alexander B, Easton DF, Pharoah PD: Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet; 2008 Apr 25;4(4):e1000054
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.
  • A three-stage genome-wide association study recently identified single nucleotide polymorphisms (SNPs) in five loci (fibroblast growth receptor 2 (FGFR2), trinucleotide repeat containing 9 (TNRC9), mitogen-activated protein kinase 3 K1 (MAP3K1), 8q24, and lymphocyte-specific protein 1 (LSP1)) associated with breast cancer risk.
  • We investigated whether the associations between these SNPs and breast cancer risk varied by clinically important tumor characteristics in up to 23,039 invasive breast cancer cases and 26,273 controls from 20 studies.
  • This SNP was also more strongly related to PR-positive, low grade and node positive tumors (P = 10(-5), 10(-8), 0.013, respectively).
  • The association for rs13281615 in 8q24 was stronger for ER-positive, PR-positive, and low grade tumors (P = 0.001, 0.011 and 10(-4), respectively).
  • The differences in the associations between SNPs in FGFR2 and 8q24 and risk by ER and grade remained significant after permutation adjustment for multiple comparisons and after adjustment for other tumor characteristics.
  • rs13281615 in 8q24 was associated with an improvement in survival after diagnosis (per-allele HR = 0.90 (0.83-0.97).
  • The association was attenuated and non-significant after adjusting for known prognostic factors.
  • Our findings show that common genetic variants influence the pathological subtype of breast cancer and provide further support for the hypothesis that ER-positive and ER-negative disease are biologically distinct.
  • Understanding the etiologic heterogeneity of breast cancer may ultimately result in improvements in prevention, early detection, and treatment.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Histol Cytol. 2004 Dec;67(5):455-64 [15781986.001]
  • [Cites] Nat Genet. 2007 May;39(5):631-7 [17401366.001]
  • [Cites] Oncogene. 1991 Apr;6(4):659-63 [1851551.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):954-6 [17618282.001]
  • [Cites] Breast Cancer Res. 2004;6(6):240-5 [15535853.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2541-6 [9703907.001]
  • [Cites] Oncol Rep. 1998 May-Jun;5(3):577-83 [9538155.001]
  • [Cites] Cancer Biol Ther. 2007 Jul;6(7):1143-7 [17630503.001]
  • [Cites] Br J Cancer. 1992 Aug;66(2):273-80 [1380281.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Breast Cancer Res. 2006;8(4):R43 [16859501.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Nat Genet. 2007 Jul;39(7):865-9 [17529974.001]
  • [Cites] Int J Cancer. 1995 Apr 10;61(2):170-6 [7705943.001]
  • [Cites] Nat Genet. 2007 Jul;39(7):870-4 [17529973.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):207-15 [15300014.001]
  • [Cites] Nat Genet. 2007 May;39(5):645-9 [17401363.001]
  • [Cites] Nat Genet. 2007 May;39(5):638-44 [17401364.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68 [15466970.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):179-86 [15863033.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):229-34 [11564899.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):989-94 [17618283.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):984-8 [17618284.001]
  • [Cites] Breast Cancer Res Treat. 2005 Mar;90(2):127-37 [15803359.001]
  • [Cites] Clin Exp Metastasis. 2000;18(7):573-80 [11688962.001]
  • [Cites] Lancet Oncol. 2006 Nov;7(11):910-8 [17081916.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Lab Invest. 2004 Nov;84(11):1460-71 [15311216.001]
  • (PMID = 18437204.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ; United Kingdom / Cancer Research UK / / ; United States / NCI NIH HHS / CA / P50 CA116201; United Kingdom / Cancer Research UK / / 11021; United Kingdom / Cancer Research UK / / 10119; United States / NCI NIH HHS / CA / R01 CA122340; United Kingdom / Cancer Research UK / / 10118; United Kingdom / Cancer Research UK / / 10124
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LSP1 protein, human; 0 / Microfilament Proteins; 0 / Receptors, Progesterone; 0 / TNRC9 protein, human; EC 2.7.10.1 / FGFR2 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2; EC 2.7.11.25 / MAP Kinase Kinase Kinase 1; EC 2.7.11.25 / MAP3K1 protein, human
  • [Other-IDs] NLM/ PMC2291027
  •  go-up   go-down


98. Lu D, Hickey AJ: Liposomal dry powders as aerosols for pulmonary delivery of proteins. AAPS PharmSciTech; 2005 Dec 21;6(4):E641-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lyophilization of liposomes, micronization of the powders, aerosolization using a dry powder inhaler (DPI), and in vitro aerodynamic fine particle fraction upon collection in a twin-stage liquid impinger were evaluated.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(4):277-83 [10071977.001]
  • [Cites] Eur J Pharm Sci. 2000 Jan;9(3):253-8 [10594381.001]
  • [Cites] Infect Immun. 2000 Dec;68(12):6826-32 [11083801.001]
  • [Cites] Int J Pharm. 2001 May 7;218(1-2):63-73 [11337150.001]
  • [Cites] J Pharm Sci. 2001 Oct;90(10):1647-57 [11745723.001]
  • [Cites] J Mol Biol. 2002 Jan 18;315(3):325-37 [11786015.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2003 Mar;30(3):153-6 [12603343.001]
  • [Cites] BMC Biotechnol. 2002 May 10;2:9 [12003642.001]
  • [Cites] AAPS PharmSciTech. 2001;2(4):25 [14727862.001]
  • [Cites] J Control Release. 2004 Feb 10;94(2-3):259-72 [14744478.001]
  • [Cites] J Pharm Sci. 1971 Oct;60(10):1559-64 [5129375.001]
  • [Cites] Anal Biochem. 1980 May 1;104(1):10-4 [6892980.001]
  • [Cites] Clin Chem. 1982 Jan;28(1):83-6 [6799227.001]
  • [Cites] Biochim Biophys Acta. 1983 Dec 12;749(2):133-42 [6652094.001]
  • [Cites] Antimicrob Agents Chemother. 1991 Jul;35(7):1448-53 [1929307.001]
  • [Cites] Pediatr Pulmonol. 1991;11(4):318-27 [1758756.001]
  • [Cites] Biochimie. 1991 Oct;73(10):1295-302 [1782223.001]
  • [Cites] Pharm Res. 1992 Apr;9(4):515-20 [1495897.001]
  • [Cites] Acta Physiol Scand. 1993 Feb;147(2):173-8 [8475743.001]
  • [Cites] Am J Physiol. 1995 Mar;268(3 Pt 1):L374-80 [7900818.001]
  • [Cites] Pharm Res. 1995 Mar;12(3):356-9 [7617520.001]
  • [Cites] Scand J Clin Lab Invest. 1996 May;56(3):251-8 [8761529.001]
  • [Cites] Biochem Pharmacol. 1996 Nov 22;52(10):1515-20 [8937465.001]
  • [Cites] Pharm Res. 1997 Sep;14(9):1151-60 [9327441.001]
  • [Cites] Int J Pharm. 1999 Apr 20;181(1):1-9 [10370197.001]
  • (PMID = 16408866.001).
  • [ISSN] 1530-9932
  • [Journal-full-title] AAPS PharmSciTech
  • [ISO-abbreviation] AAPS PharmSciTech
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL67221-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Liposomes; 0 / Powders; 0 / Proteins
  • [Other-IDs] NLM/ PMC2750613
  •  go-up   go-down


99. Kipp BR, Tanasescu M, Else TA, Bryant SC, Karnes RJ, Sebo TJ, Halling KC: Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer. J Mol Diagn; 2009 Mar;11(2):148-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer.
  • Fluorescence in situ hybridization (FISH) testing is used to detect bladder cancer in urine specimens.
  • The purpose of this study was to determine whether there are associations between the percentage of chromosomally abnormal cells by FISH and time to bladder cancer recurrence and progression to metastasis.
  • Clinical records were searched to identify patients with urine FISH results, history of non-invasive bladder cancer, and at least one follow-up pathological diagnosis.
  • Covariates analyzed included age, gender, smoking status, treatment after FISH, cystoscopy result, and prior stage of bladder cancer.
  • The percentage of abnormal cells (hazard ratio [HR] 1.03, 95% CI 1.02-1.03; P < 0.001), age (HR 1.02, 95% CI 1.00-1.03; P = 0.033), male gender (HR 0.60, 95% CI 0.41-0.87; P < 0.001), treatment (HR 0.37, 95% CI 0.25-0.55; P < 0.001), and history of TIS/T1-stage tumors (HR 1.66, 95% CI 1.23-2.24; P = 0.001) were significantly associated with time to cancer recurrence.
  • Time to invasive cancer was significantly associated with the percentage of abnormal cells (HR 1.02, 95% CI 1.01, 1.03; P < 0.001), history of TIS/T1 tumor (HR 3.73, 95% CI 1.88, 7.38; P = 0.001), and treatment (HR 0.33, 95% CI 0.13, 0.83; P = 0.019), suggesting that the percentage of abnormal cells independently predicts cancer recurrence and progression to invasive disease in patients with a history of non-invasive bladder cancer.
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Neoplasm Invasiveness / diagnosis. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 Feb;173(2):401-4 [15643180.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5519-27 [17158537.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):295-301 [17210520.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Curr Opin Oncol. 2007 May;19(3):241-7 [17414643.001]
  • [Cites] Urol Oncol. 2004 Jan-Feb;22(1):16-9 [14969798.001]
  • [Cites] Am J Clin Pathol. 2001 Jul;116(1):79-86 [11447756.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Dec;23(6):381-7 [11777271.001]
  • [Cites] J Urol. 2002 Nov;168(5):1950-4 [12394683.001]
  • [Cites] J Urol. 2003 Jun;169(6):2101-5 [12771727.001]
  • [Cites] Anal Quant Cytol Histol. 2008 Jun;30(3):145-51 [18630839.001]
  • (PMID = 19179455.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2665864
  •  go-up   go-down


100. Gunia S, May M, Koch S, Dietel M, Erbersdobler A: MUC1 expression in incidental prostate cancer predicts staging and grading on the subsequent radical prostatectomy. Pathol Oncol Res; 2010 Sep;16(3):371-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC1 expression in incidental prostate cancer predicts staging and grading on the subsequent radical prostatectomy.
  • The behavior of Incidental prostate cancer (IPC) cannot be reliably predicted by means of conventional histomorphology.
  • MUC1 (episialin) expression has been linked to poor outcome in peripheral prostate cancer (PC).
  • We aimed to determine the so far neglected prognostic role of MUC1 expression in IPC which most commonly represents transition zone cancer.
  • MUC1 expression was present in 7 (15.9%) of the 44 IPC immunohistochemically investigated with a striking over-representation in high stage tumors, and was significantly correlated with histopathologic staging (ρ = 0.4; p = 0.02) and Gleason scores (ρ = 0.3; p = 0.03) performed on the corresponding RPs.
  • Our findings suggest that MUC1 might become a valuable adjunct to enable individual prognostic ramification prior to radical surgery in prostate cancer histologically detected in TURP chips.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2009 Jun;103(11):1478-81 [19076134.001]
  • [Cites] Curr Cancer Drug Targets. 2007 May;7(3):259-71 [17504123.001]
  • [Cites] Eur J Hum Genet. 2008 Dec;16(12):1521-5 [18628787.001]
  • [Cites] Semin Surg Oncol. 1995 Jan-Feb;11(1):36-45 [7538693.001]
  • [Cites] Pathol Int. 1994 Jul;44(7):487-504 [7921193.001]
  • [Cites] J Urol. 1980 Nov;124(5):626-31 [7452789.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):426-31 [18091386.001]
  • [Cites] Histol Histopathol. 2007 Aug;22(8):905-22 [17503348.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Virchows Arch. 2009 May;454(5):573-9 [19301031.001]
  • [Cites] Urologe A. 2005 Sep;44(9):1052, 1054-8 [15965641.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):49-55 [16773184.001]
  • [Cites] Anal Quant Cytol Histol. 2008 Apr;30(2):71-7 [18561742.001]
  • [Cites] Histol Histopathol. 2007 Aug;22(8):889-93 [17503346.001]
  • [Cites] Am J Respir Cell Mol Biol. 1992 Dec;7(6):557-64 [1449803.001]
  • (PMID = 19943130.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down






Advertisement